Recombinant adenoviruses and use thereof

Novel simian adenoviruses sAd4287, sAd4310A, and sAd4312 offer a solution to the limitations of Ad5-based vaccines by providing low seroprevalence and high immunogenicity, making them suitable for developing effective vaccines against HIV and cancer.

JP2024160183AInactive Publication Date: 2024-11-12BETH ISRAEL DEACONESS MEDICAL CENT INC +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024112088
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2012-11-16
Filing Date
2024-07-12
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The utility of adenovirus serotype 5 (Ad5)-based vaccines is limited by high pre-existing anti-Ad5 immunity in the human population, leading to reduced immunogenicity and efficacy against pathogens such as HIV.

Method used

Development of novel simian adenoviruses, sAd4287, sAd4310A, and sAd4312, with low seroprevalence and strong immunogenicity, providing alternative recombinant adenoviral vectors for vaccine development, including sequences for fiber and hexon proteins and potential use in chimeric vectors with other adenoviral backbones.

Benefits of technology

These novel adenoviral vectors exhibit low baseline anti-vector immunity and strong immunogenicity, suggesting their potential as effective vaccine candidates against diseases like HIV and cancer, inducing robust immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160183000284
    Figure 2024160183000284
  • Figure 2024160183000285
    Figure 2024160183000285
  • Figure 2024160183000286
    Figure 2024160183000286
Patent Text Reader

Abstract

To provide alternative adenoviral vectors that have low seroprevalence and potent immunogenicity.SOLUTION: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with Government support under Grant Nos. AI078526, AI096040, and OD011170 awarded by the National Institutes of Health (NIH). The Government has certain rights in the invention.

[0002] Recombinant adenovirus vectors have been used in vaccine development. Up to now, about 55 different adenovirus serotypes have been identified. Subgroup C adenoviruses have been most widely studied in applications such as vaccination and gene therapy. In particular, adenovirus serotypes 2 and 5 (Ad2 and Ad5) have been widely used in the field. Importantly, Ad5 vector-based vaccines have been shown to induce strong and protective immune responses in various animal models. In addition, large-scale clinical trials for HIV vaccination using Ad5-based recombinant vectors are ongoing (see, for example, WO 01 / 02607; WO 02 / 22080; Shiver et al., Nature. 415:331-335, 2002; Letvin et al., Annu. Rev. Immunol. 20:73-99, 2002; and Shiver and Emini, annu. Rev. Med. 55:355, 2004).

[0003] However, the utility of recombinant Ad5 vector-based vaccines against HIV and other pathogens may be limited due to high pre-existing anti-Ad5 immunity in human populations. The presence of anti-Ad5 immunity correlates with reduced immunogenicity of Ad5-based vaccines in studies in mice and rhesus monkeys. Early data from phase 1 clinical trials indicate that this problem may also arise in humans. Ad5-specific neutralizing antibodies (NAbs) and CD8 +Although both IgG and T lymphocytes contribute to anti-Ad5 immunity, Ad5-specific NAbs appear to play a major role in this process (Sumida et al., J. Virol., 174:7179-7185, 2004). Summary of the Invention [Problem to be solved by the invention]

[0004] Thus, there is an unmet need in the field for alternative adenoviral vectors that have low seroprevalence and strong immunogenicity. [Means for solving the problem]

[0005] Summary of the Invention The entire genomes of three novel simian adenoviruses (sAds), sAd4287, sAd4310A, and sAd4312, have been identified and determined. These adenoviruses unexpectedly exhibit both low seroprevalence and strong immunogenicity, suggesting that these viruses may be useful as novel vaccine vector candidates. In a first aspect, the invention features an isolated polynucleotide comprising a nucleotide sequence at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of any one of SEQ ID NOs: 1-3, or a complement thereof. SEQ ID NOs: 1, 2, and 3 are the full-length genome sequences of wild-type sAd4287, sAd4310A, and sAd4312, respectively. An isolated polynucleotide of the present invention may comprise at least 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 25000, 30000, or 35000 or more contiguous or noncontiguous nucleotides of a reference polynucleotide molecule (e.g., SEQ ID NOs: 1-3).

[0006] In some embodiments, an isolated polynucleotide of the invention comprises a nucleotide sequence that is at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of any one of SEQ ID NOs:4-12, or a complement thereof. SEQ ID NOs:4-12 feature nucleotide sequences encoding the fiber 1, fiber 2, and hexon proteins of wild-type sAd4287, sAd4310A, and sAd4312. Thus, in some embodiments, a nucleotide sequence encoding all or a portion of a fiber-1 protein can be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding the fiber-1 protein of wild-type sAd4287, sAd4310A, or sAd4312, which correspond to SEQ ID NOs:4, 5, and 6, respectively. In some embodiments, a nucleotide sequence encoding all or a portion of a fiber 2 protein can be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding the fiber 2 protein of wild-type sAd4287, sAd4310A, or sAd4312, which correspond to SEQ ID NOs:7, 8, and 9, respectively. In some embodiments, a nucleotide sequence encoding all or a portion of a hexon protein may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding the hexon protein of wild-type sAd4287, sAd4310A, or sAd4312, corresponding to SEQ ID NOs: 10, 11, and 12, respectively.In some embodiments, the nucleotide sequence comprises one or more hexon protein hypervariable regions (HVRs) (e.g., HVR1 (nt 403 to nt 489), HVR2 (nt 520 to nt 537), HVR3 (nt 592 to nt 618), HVR4 (nt 706 to nt 744), HVR5 (nt 763 to 786), HVR6 (nt 856 to nt 874), and / or HVR7 (nt 1201 to nt 1296) (SEQ ID NO: 10) of sAd4287 hexon protein; HVR1 (nt 403 to nt 477), HVR2 (nt 505 to nt 516), HVR3 (nt 571 to nt 591), HVR4 (nt 679 to nt 690), HVR5 (nt 709 to 735), HVR6 (nt 856 to nt 874), and / or HVR7 (nt 1201 to nt 1296) of sAd4310A hexon protein). or HVR1 (nt 403 to nt 474), HVR2 (nt 505 to nt 522), HVR3 (nt 577 to nt 597), HVR4 (nt 685 to nt 726), HVR5 (nt 748 to 777), HVR6 (nt 847 to nt 864), and / or HVR7 (nt 1192 to nt 1284) (SEQ ID NO: 12)) of sAd4312 hexon protein.

[0007] In some embodiments, one or more nucleotide sequences encoding one or more hexon protein hypervariable regions (HVRs) of the invention may be used in combination with those of another virus (e.g., HVR1 (nt 403 to nt 489), HVR2 (nt 520 to nt 537), HVR3 (nt 592 to nt 618), HVR4 (nt 706 to nt 744), HVR5 (nt 763 to 786), HVR6 (nt 856 to nt 906) of sAd4287 hexon protein). HVR1 (nt 403 to nt 477), HVR2 (nt 505 to nt 516), HVR3 (nt 571 to nt 591), HVR4 (nt 679 to nt 690), HVR5 (nt 709 to 735), HVR6 (nt 805 to nt 816), and / or HVR7 (nt 1144 to nt 1 236) (SEQ ID NO: 11); or HVR1 (nt 403 to nt 474), HVR2 (nt 505 to nt 522), HVR3 (nt 577 to nt 597), HVR4 (nt 685 to nt 726), HVR5 (nt 748 to 777), HVR6 (nt 847 to nt 864), and / or HVR7 (nt 1192 to nt 1284) (SEQ ID NO: 12)) of the sAd4312 hexon protein, In one embodiment, the nucleotide sequence is replaced with the corresponding HVR sequence of one or more other viruses, e.g., adenoviruses, e.g., adenoviruses with lower seroprevalence than Ad5, e.g., adenoviruses of subgroup B (Ad11, Ad34, Ad35, and Ad50) and subgroup D (Ad15, Ad24, Ad26, Ad48, and Ad49), and simian adenoviruses (e.g., Pan9, also known as AdC68). In another embodiment, the nucleotide sequence comprises an adenovirus vector backbone of Ad5, Ad11, Ad15, Ad24, Ad26, Ad34, Ad48, Ad49, Ad50, or Pan9 / AdC68 with a replacement of all or part of one or more of the above hexon HVRs of sAd4287, sAd4310A, and / or sAd4312.

[0008] In some embodiments, an isolated polynucleotide of the invention comprises a nucleotide sequence that is at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of any one of SEQ ID NOs: 13-18, or a complement thereof. SEQ ID NOs: 13-18 feature nucleotide sequences encoding the knob domains of fiber 1 and fiber 2 proteins of wild-type sAd4287, sAd4310A, and sAd4312. In some embodiments, a nucleotide sequence encoding all or a portion of the knob domain of fiber 1 can be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to a nucleotide sequence encoding the knob domain of a wild-type sAd4287, sAd4310A, or sAd4312 fiber 1 protein, corresponding to SEQ ID NOs: 13, 14, and 15, respectively. In some embodiments, a nucleotide sequence encoding all or a portion of the fiber 2 knob domain can be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to a nucleotide sequence encoding the knob domain of a wild-type sAd4287, sAd4310A, or sAd4312 fiber 2 protein, corresponding to SEQ ID NOs: 16, 17, and 18, respectively. In some embodiments, one or more of the nucleotide sequences encoding the knob domain of a fiber protein of the invention (e.g., fiber 1 or fiber 2 protein) (SEQ ID NOs: 13-18) can be replaced with that of another virus.

[0009] In a second aspect, the invention features a recombinant vector comprising an isolated polynucleotide of the invention, the recombinant vector comprising a nucleotide sequence that is at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of any one of SEQ ID NOs: 34-51. In some embodiments, the vector is an sAd4297 adenoviral vector that comprises all or a portion of any one of SEQ ID NOs: 34-39. In some embodiments, the vector is an sAd4310A adenoviral vector that comprises all or a portion of any one of SEQ ID NOs: 40-45. In some embodiments, the vector is an sAd4312 adenoviral vector that comprises all or a portion of any one of SEQ ID NOs: 46-51. In another embodiment, to produce the recombinant adenovirus of the present invention, a plasmid system may be established using two or more (for example, two, three, or four) of the vectors represented by SEQ ID NOs: 34 to 51.

[0010] In embodiments of the first or second aspect of the invention, an isolated polynucleotide and / or recombinant vector is used to generate a recombinant adenovirus, where all or a portion of the adenovirus is derived from any one of SEQ ID NOs: 1-3. In some embodiments, the recombinant adenovirus comprises an isolated polynucleotide that includes a deletion in or of the E1 region (e.g., nt 474 to nt 3085 of sAd4287 (SEQ ID NO: 1); nt 474 to nt 3088 of sAd4310A (SEQ ID NO: 2); and nt 487 to nt 3100 of sAd4312 (SEQ ID NO: 3)). The recombinant adenoviral vector containing this deletion becomes replication-deficient. In some embodiments, the replication-deficient virus may also comprise a deletion in or of the E3 region (e.g., nt 25973 to nt 28596 of sAd4287 (SEQ ID NO: 1); nt 25915 to nt 28496 of sAd4310A (SEQ ID NO: 2); and nt 25947 to nt 28561 of sAd4312 (SEQ ID NO: 3)), and / or a deletion in or of the E4 region (e.g., nt 31852 to nt 34752 of sAd4287 (SEQ ID NO: 1); nt 31750 to nt 34048 of sAd4310A (SEQ ID NO: 2); and nt 31818 to nt 34116 of sAd4312 (SEQ ID NO: 3)). In other embodiments, the recombinant adenovirus comprises one or more of the E1, E3, and / or E4 regions and is replication-competent.

[0011] According to preferred embodiments, the recombinant adenovirus further comprises a heterologous nucleotide sequence encoding an antigenic or therapeutic gene product of interest, or a fragment thereof. In some embodiments, the antigenic gene product, or a fragment thereof, comprises a bacterial, viral, parasitic, or fungal protein, or a fragment thereof.

[0012] The bacterial proteins, or fragments thereof, may be derived from Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, Mycobacterium leprae, Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Francisella tularensis, Brucella, Burkholderia The gene product may be obtained from Mycobacterium strains such as Mycobacterium spp., ...

[0013] Viral proteins, or fragments thereof, include viruses from the Retroviridae family, including human immunodeficiency virus (HIV; e.g., types 1 and 2), and human T-lymphotropic virus types I and II (HTLV-1 and HTLV-2, respectively); the Flaviviridae family, including hepatitis C virus (HCV), yellow fever virus (e.g., members of the genera Flavivirus, Pestivirus, and Hepacivirus); tick-borne viruses, such as Gadgets Gully virus, Kadam virus, Kyasanur Forest disease virus, Langat virus, Omsk hemorrhagic fever virus, and the like; virus, Powassan virus, Royal Farm virus, Karshi virus, tick-borne encephalitis virus, Neudoerfl virus, Sofjin virus, Louping ill virus and Negishi virus; seabird tick-borne viruses, such as Meaban virus, Saumarez Reef virus and Tyuleniy virus;Mosquito-borne viruses, such as Aroa virus, dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Usutu virus, West Nile virus, Yaounde virus, Kokobera virus, Bagaza virus, Ilheus virus, Israel turkey meningoencephalo-myelitis virus, Ntaya virus, Tembusu virus, virus, Zika virus, Banzi virus, Bouboui virus, Edge Hill virus, Jugra virus, Saboya virus, Sepik virus, Uganda S virus, Wesselsbron virus, yellow fever virus;and viruses without known arthropod vectors, such as Entebbe bat virus, Yokose virus, Apoi virus, Cowbone Ridge virus, Jutiapa virus, Modoc virus, Sal Vieja virus, San Perlita virus, Bukalasa bat virus, Carey Island virus, Dakar bat virus, Montana myotis leukoencephalitis virus, Phnom Penh bat virus, Rio Bravo virus, Tamana bat virus, and cell fusing agent virus);Ippy virus, Lassa virus (e.g., Josiah, LP, or GA391 strains), lymphocytic choriomeningitis virus (LCMV), Mobala virus, Mopeia virus, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Parana virus, Pichinde virus, Pirital virus, Sabia virus, Tacaribe virus, Tamiami virus, Whitewater Arroyo virus, the Arenaviridae family, including Arenavirus, Chaparevirus, and Lujovirus;The family Bunyaviridae (e.g., members of the genera Hantavirus, Nairovirus, Orthobunyavirus, and Phlebovirus), including Hantaan virus, Sin Nombre virus, Dugbe virus, Bunyamwera virus, Rift Valley fever virus, La Crosse virus, Punta Toro virus (PTV), California encephalitis virus, and Crimean-Congo hemorrhagic fever (CCHF) virus; the family Bunyaviridae (e.g., members of the genera Hantavirus, Nairovirus, Orthobunyavirus, and Phlebovirus); the family Ebola virus (e.g., members of the genera Zaire, Sudan, Ivory Coast the Filoviridae family, including Filoviridae virus (e.g., Angola, Ci67, Musoke, Popp, Ravn, and Lake Victoria strains) and Marburg virus (e.g., Angola, Ci67, Musoke, Popp, Ravn, and Lake Victoria strains);Togaviridae family (e.g., members of the genus Alphavirus), including Venezuelan equine encephalitis virus (VEE), Eastern equine encephalitis virus (EEE), Western equine encephalitis virus (WEE), Sindbis virus, rubella virus, Semliki Forest virus, Ross River virus, Barmah Forest virus, O'nyong'nyong virus, and chikungunya virus; smallpox virus, monkeypox virus, and vaccinia virus; the Poxviridae family, including the genus Orthopoxvirus; the Herpesviridae family, including the herpes simplex virus (HSV; types 1, 2, and 6), human herpes virus (e.g., types 7 and 8), cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-Zoster virus, and Kaposi's sarcoma associated-herpesvirus (KSHV);Influenza viruses (A, B, and C), such as the Orthomyxoviridae family, including H5N1 avian influenza virus or H1N1 swine flu; the Coronaviridae family, including the severe acute respiratory syndrome (SARS) virus; the Rhabdoviridae family, including rabies virus and vesicular stomatitis virus (VSV); human respiratory syncytial virus (RSV), Newcastle disease virus, Hendra virus, Nipah virus, measles virus, rinderpest virus, canine distemper virus, and the like. the Paramyxoviridae family, including the viruses Sendai, human parainfluenza (e.g., types 1, 2, 3, and 4), rhinoviruses, and mumps viruses; The Picornaviridae family includes poliovirus, human enterovirus (A, B, C, and D), hepatitis A virus, and coxsackievirus; the Hepadnaviridae family includes hepatitis B virus; the Papillomaviridae family includes human papillomavirus; the Parvoviridae family includes adeno-associated viruses; the Astroviridae family includes astrovirus; the Polyomaviridae family includes JC virus, BK virus, and SV40 virus; The viral vector may be derived from a virus of the Calciviridae family, including Calicivirus; or the Reoviridae family, including rotavirus.In a preferred embodiment, the viral protein, or fragment thereof, is selected from the group consisting of human immunodeficiency virus (HIV), human papillomavirus (HPV), hepatitis A virus (Hep A), hepatitis B virus (HBV), hepatitis C virus (HCV), Variola major, Variola minor, monkeypox virus, measles virus, rubella virus, mumps virus, varicella zoster virus (VZV), poliovirus, rabies virus, Japanese encephalitis virus, herpes simplex virus, and the like. The viral protein, or fragment thereof, is derived from HIV Gag, Pol, Env, Nef, Tat, Rev, Vif, Vpr, or Vpu.

[0014] The parasite protein, or fragment thereof, may be derived from Toxoplasma gondii, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Trypanosoma spp., or Legionella spp. Examples of particular preferred parasite proteins that can be cloned into the vectors of the invention include those derived from Plasmodium falciparum, such as the circumsporozoite (CS) protein and Liver Specific Antigens 1 or 3 (LSA-1 or LSA-3).

[0015] The fungal protein, or fragment thereof, may be from Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus, or Rhizopus aridis. Examples of fungal gene products, or fragments thereof, include any cell wall mannoprotein (e.g., Afmp1 from Aspergillus fumigatus) or surface-expressed glycoprotein (e.g., SOWgp from Coccidioides immitis).

[0016] Therapeutic gene products, or fragments thereof, may be derived from interferon (IFN) proteins, factor VIII, factor IX, erythropoietin, alpha-1 antitrypsin, calcitonin, glucocerebrosidase, growth hormone, low density lipoprotein (LDL), the receptor IL-2 receptor and its antagonists, insulin, globins, immunoglobulins, catalytic antibodies, interleukins, insulin-like growth factors, superoxide dismutase, immune responder modifiers, parathyroid hormone and interferons, nerve growth factor, tissue plasminogen activator, and / or colony stimulating factors, or fragments thereof.

[0017] The third aspect of the invention features a method of treating a subject (e.g., a human) with a disease (e.g., HIV or cancer) by administering to the subject a recombinant sAd adenovirus vector of the second aspect of the invention. In a preferred embodiment, the recombinant sAd adenovirus of the invention comprises an antigenic gene product, or a fragment thereof, that promotes an immune response against an infectious agent in a subject at risk of exposure to or exposed to the infectious agent. In some embodiments, the infectious agent is a bacterium, a virus, a parasite, or a fungus, such as those described above. In one non-limiting example, administering to a subject who is HIV positive or has acquired immune deficiency syndrome (AIDS) an sAd adenovirus of the invention expressing an HIV Gag protein or a fragment thereof can stimulate an immune response against HIV in the subject, thereby treating the subject. In another embodiment, the recombinant sAd adenovirus of the invention comprises a therapeutic gene product or fragment thereof, such as an interferon (IFN) protein, or fragment thereof, that provides therapy for a subject having a disease induced by a non-infectious agent, such as cancer, by stimulating a favorable immune response against the tumor in the subject and / or providing gene therapy, thereby treating the subject. Other non-limiting examples of treatable diseases include any human health disease, such as tuberculosis, leprosy, typhoid fever, pneumonia, meningitis, Staphylococcal exfoliative syndrome (SSSS), Litter's disease, tularemia (rabbit fever), brucellosis, glanders, bubonic plague, septicemic plague, pneumonic plague, diphtheria, whooping cough, tetanus, anthrax, hepatitis, smallpox, monkeypox, measles, mumps, rubella, chicken pox, polio, rabies, Japanese encephalitis, herpes, mononucleosis, rabies ... Influenza, Ebola virus disease, hemorrhagic fever, yellow fever, Marburg disease, toxoplasmosis, malaria, trypanosomiasis, legionnaires' disease, aspergillosis, blastomycosis, candidiasis (thrush), coccidioidomycosis, cryptococcosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis, or sinus-orbital zygomycosis.Treatment of these diseases may be by administration of recombinant sAd vectors of the invention that encode or express on their surface an antigen that stimulates an immune response from a selected infectious agent.

[0018] In some embodiments, the recombinant adenovirus or adenoviral vector is administered intramuscularly, intravenously, intradermally, percutaneously, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrathoracically, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by direct local perfusion bathing target cells, by catheter, by lavage, by tube feeding, as a cream, or as a lipid composition. In one preferred embodiment, the recombinant adenovirus or adenoviral vector is administered as a pharmaceutical composition comprising a pharma- ceutically acceptable carrier, diluent, or excipient, and may optionally comprise an adjuvant. In some embodiments, the subject is administered at least one dose (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) of the composition. In other embodiments, the subject is administered at least two doses (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more doses) of the composition. In yet another embodiment, the pharmaceutical composition is administered to the subject as a prime boost or in a prime boost regimen. The subject is administered at least about 1×10 3 viral particles (vp) / dose or 1 x 10 1 ~1×10 14 vp / dose, preferably 1 x 10 3 ~1×10 12 vp / dose, more preferably 1 x 10 5 ~1×10 11It may be administered in vp / dose. The pharmaceutical composition may be administered to the subject, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 35, 40, 45, 50, 55, or 60 minutes, 2, 4, 6, 10, 15, or 24 hours, 2, 3, 5, or 7 days, 2, 4, 6, or 8 weeks, or even 3, 4, or 6 months prior to exposure or diagnosis to an infectious agent, or may be administered to the subject 15-30 minutes or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 20, 24, 48, or 72 hours, 2, 3, 5, or 7 days, 2, 4, 6, or 8 weeks, 3, 4, 6, or 9 months, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 years or more after diagnosis or exposure. When treating a disease (e.g., AIDS or cancer), the pharmaceutical compositions of the invention may be administered to a subject prior to the onset or definitive diagnosis of symptoms or after the diagnosis or symptoms become evident. The pharmaceutical compositions may be administered, for example, immediately after diagnosis or clinical recognition of the symptoms, or 2, 4, 6, 10, 15, or 24 hours, 2, 3, 5, or 7 days, 2, 4, 6, or 8 weeks, or even 3, 4, or 6 months after diagnosis or detection of the symptoms.

[0019] In a fourth aspect, the invention features a method of producing a recombinant adenovirus of the invention, comprising culturing a cell in a suitable medium; transfecting the cell with an isolated polynucleotide of the first aspect of the invention or a recombinant vector of the second aspect of the invention; allowing the polynucleotide or vector to replicate in the cell; and recovering the produced recombinant adenovirus from the medium and / or the cell. In some embodiments, the cell is a bacterial, plant, or mammalian cell. In a preferred embodiment, the mammalian cell is a PER.55K cell or a Chinese Hamster Ovary (CHO) cell.

[0020] definition "Adenovirus" refers to a medium-sized (90-100 nm), non-enveloped icosahedral virus containing a capsid and a double-stranded linear DNA genome. The adenovirus may be a naturally occurring or isolated adenovirus (e.g., sAd4287, sAd4310A, or sAd4312) or a recombinant adenovirus (e.g., replication-deficient or replication-competent sAd4287, sAd4310A, or sAd4312, or chimeric mutants thereof).

[0021] "Administering" as used herein refers to a method of administering a dose of a pharmaceutical composition (e.g., a recombinant adenovirus of the present invention) to a subject. The compositions utilized in the methods described herein may be administered, for example, intramuscularly, intravenously, intradermally, transdermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrathoracically, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilical cavities, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by direct local irrigation bathing target cells, by catheter, by lavage, by tube feeding, as a cream, or as a lipid composition. The preferred method of administration may vary depending on various factors, such as the components of the composition being administered and the severity of the condition being treated.

[0022] Throughout this patent specification and the claims, the term "comprise" or variations such as "comprises" or "comprising" will be understood to mean the inclusion of a stated integer or group of integers, but not the exclusion of any other integers or groups of integers.

[0023] A "deletion" of an adenoviral genomic region refers to the partial or complete removal, disruption (e.g., by insertion mutation), or functional inactivation (e.g., by missense mutation) of a particular genomic region (e.g., the E1, E2, E3, and / or E4 regions), or any particular open reading frame within a particular region.

[0024] "Gene product" is meant to include mRNA or other nucleic acid (e.g., microRNA) transcribed from a gene as well as polypeptides translated from the mRNA. In some embodiments, the gene product may be derived from a virus (e.g., HIV), and many include, for example, any one or more viral proteins, or fragments thereof, as described, for example, in pending U.S. Patent Application Publication No. 2012 / 0076812. In some embodiments, the gene product is a therapeutic gene product, including, but not limited to, interferon proteins, factor VIII, factor IX, erythropoietin, alpha-1 antitrypsin, calcitonin, glucocerebrosidase, growth hormone, low density lipoprotein (LDL), receptor IL-2 receptor and its antagonists, insulin, globins, immunoglobulins, catalytic antibodies, interleukins, insulin-like growth factors, superoxide dismutase, immune responder modifier, parathyroid hormone and interferons, nerve growth factor, tissue plasminogen activator, and colony stimulating factors.

[0025] "Heterologous nucleic acid molecule" refers to any exogenous nucleic acid molecule that can be incorporated into, for example, an adenovirus of the invention, or a polynucleotide or vector thereof, with the intent of subsequent expression of the gene product of interest, or a fragment thereof, encoded by the heterologous nucleic acid molecule. In a preferred embodiment, the heterologous nucleic acid molecule encodes an antigenic or therapeutic gene product, or a fragment thereof, that is a bacterial, viral, parasitic, or fungal protein, or a fragment thereof (e.g., a nucleic acid molecule encoding one or more HIV or SIV Gag, Pol, Env, Nef, Tat, Rev, Vif, Vpr, or Vpu gene products, or a fragment thereof). A heterologous nucleic acid molecule is one that is not normally associated with other nucleic acid molecules found in a wild-type adenovirus.

[0026] "Isolated" means separated, recovered or purified from a component of its natural environment.

[0027] "Pharmaceutical composition" refers to any composition suitable for administration to a subject and containing a therapeutic or bioactive agent, e.g., a recombinant adenoviral vector of the invention, preferably comprising a heterologous nucleotide sequence encoding an antigen or therapeutic gene product of interest, or a fragment thereof, that treats a disease (e.g., cancer or AIDS) or reduces or ameliorates one or more symptoms of a disease. For purposes of the present invention, pharmaceutical compositions include vaccines, and pharmaceutical compositions suitable for delivery of therapeutic or bioactive agents may include, for example, tablets, gelcaps, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels, hydrogels, oral gels, pastes, eye drops, ointments, creams, plasters, drenches, delivery devices, suppositories, enemas, injections, implants, sprays, or aerosols. Any of these formulations may be prepared by methods well known and recognized in the art. See, for example, Remington: The Science and Practice of Pharmacy (21 sted.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2005, and Encyclopedia of Pharmaceutical Technology, ed. J. Swarbrick, Informa Healthcare, 2006, each of which is incorporated herein by reference.

[0028] "Pharmaceutically acceptable diluent, excipient, carrier, or adjuvant" means a diluent, excipient, carrier, or adjuvant that is physiologically acceptable to a subject while retaining the therapeutic properties of the pharmaceutical composition with which it is administered. One exemplary pharma-ceutically acceptable carrier is saline. Other physiologically acceptable diluents, excipients, carriers, or adjuvants and their formulations are known to those skilled in the art (see, for example, U.S. Patent Application Publication No. 2012 / 0076812).

[0029] "Part" or "fragment" refers to a portion of a whole. A part may comprise at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the entire length of a polynucleotide or polypeptide sequence region. For example, in a polynucleotide, a part may comprise at least 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 25000, 30000, 35000 or more contiguous nucleotides of a reference polynucleotide molecule. For example, in a polypeptide, a portion may include at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, or 350 or more contiguous amino acids of the reference polypeptide molecule.

[0030] "Promoting an immune response" means eliciting a humoral response (e.g., production of antibodies) or a cellular response (e.g., activation of T cells, macrophages, neutrophils, and natural killer cells) specific to, for example, one or more infectious agents (e.g., bacteria, viruses, parasites, fungi, or combinations thereof) or protein targets in a subject to which the pharmaceutical composition (e.g., vaccine) is administered.

[0031] "Recombinant" with reference to a vector or virus means a vector or virus that has been manipulated in vitro, e.g., a vector or virus that includes a heterologous nucleotide sequence (e.g., a sequence encoding an antigen or therapeutic gene product) or a vector or virus that has an alteration, disruption, or deletion in the viral E1, E3, and / or E4 regions relative to the wild-type viral E1, E3, and / or E4 regions.

[0032] "Sequence identity" or "sequence similarity" means that the identity or similarity between two or more amino acid sequences, or two or more nucleotide sequences, is expressed in terms of the identity or similarity between the sequences. Sequence identity may be measured in terms of "percentage (%) identity", with the higher the percentage, the higher the identity shared between the sequences. Sequence similarity may be measured in terms of percentage similarity (taking into account conservative amino acid substitutions), with the higher the percentage, the higher the similarity shared between the sequences. Homologs or orthologs of nucleic acid or amino acid sequences have a relatively high degree of sequence identity / similarity when aligned using standard methods. Sequence identity may be measured using sequence analysis software with default settings (e.g., Sequence Analysis Software Package from Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software allows similar sequences to be matched by assigning degrees of homology to various substitutions, deletions, and other modifications.

[0033] A "subject" is a vertebrate, such as a mammal (e.g., primates and humans). Mammals also include, but are not limited to, farm animals (such as cows), sport animals (e.g., horses), pets (such as cats and dogs), mice, and rats. A subject to be treated according to the methods described herein (e.g., a subject having a disease, such as cancer, and / or a disease caused by an infectious agent, e.g., a bacterium, a virus, a fungus, or a parasite) may be one who has been diagnosed by a physician as having such a condition. Diagnosis may be performed by any suitable means. A subject in which the development of an infection is prevented may or may not have been so diagnosed. One of skill in the art will understand that a subject to be treated according to the present invention may have undergone standard testing, or may have been identified as being at high risk by the presence of one or more risk factors (e.g., exposure to a biological agent, e.g., a virus) without testing.

[0034] As used herein and as well understood in the art, "treatment" is an approach to obtain beneficial or desired results, such as clinical results. Beneficial or desired results may include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; reduction in the extent of a disease, disorder, or condition; stabilization of the disease, disorder, or condition (i.e., not worsening); prevention of the spread of a disease, disorder, or condition; delay or slowing of the progression of a disease, disorder, or condition; recovery or alleviation of a disease, disorder, or condition; and remission (either partial or complete), either detectable or undetectable. "Alleviating" a disease, disorder, or condition means that the extent and / or undesirable clinical symptoms of a disease, disorder, or condition are alleviated and / or the time course of progression is slowed or extended, compared to the extent or time course in the absence of treatment.

[0035] The term "vaccine" as used herein is defined as a material used to induce an immune response and may confer immunity following administration of the vaccine to a subject.

[0036] "Vector" refers to a composition comprising one or more genes (nonstructural or structural), or fragments thereof, derived from a viral species, such as an adenovirus species (e.g., sAd4287, sAd4310A, or sAd4312), which can be used to deliver one or more heterologous genes from a viral or nonviral source to a host or subject. The nucleic acid material of a viral vector can be encapsulated, for example, in a lipid membrane or by structural proteins (e.g., capsid proteins), and it can include one or more viral polypeptides (e.g., glycoproteins). A viral vector can be used to infect cells of a subject, which then facilitates translation of the heterologous genes of the viral vector into a protein product.

[0037] The term "virus," as used herein, is defined as an infectious agent that is unable to grow or reproduce outside a host cell and that infects mammals (eg, humans) or birds.

[0038] Other features and advantages of the invention will become apparent from the following detailed description, the drawings, and the claims. [Brief description of the drawings]

[0039] [Figure 1] Schematic map of the genomic organization of sAd4287. [Diagram 2] 1 is a schematic map of plasmid sAdApt4287.Empty. [Diagram 3] 1 is a schematic map of plasmid pBr / sAd4287.pIX-pV. [Figure 4] 1 is a schematic map of plasmid pBr / sAd4287.PsiI-rITR. [Diagram 5]1 illustrates the cloning strategy used to obtain plasmid pBr / sAd4287.PsiI-rITR.dE3 and a schematic map of pBr / sAd4287.PsiI-rITR.dE3 relative to that of its parent plasmid pBr / sAd4287.PsiI-rITR. [Figure 6] 1 shows a schematic map of plasmid pBr / sAd4287.PsiI-rITR.dE3.dE4 relative to its parent plasmid pBr / sAd4287.PsiI-rITR.dE3. [Figure 7] 1 illustrates the cloning strategy used to obtain plasmid sAdApt4287.E1btg.Empty and a schematic map of sAdApt4287.E1btg.Empty relative to that of its parent plasmid sAdApt4287.Empty. [Figure 8] Schematic map of the genomic organization of sAd4310#13-1 (sAd4310A). [Figure 9] 1 is a schematic map of plasmid sAdApt4310A.Empty. [Figure 10] 1 is a schematic map of plasmid pBr / sAd4310A.pIX-pV. [Figure 11] 1 is a schematic map of plasmid pBr / sAd4310A.RsrII-rITR. [Figure 12] 1 shows a schematic map of pBr / sAd4310A.RsrII-rITR.dE3 relative to its parent plasmid, pBr / sAd4310A.RsrII-rITR. [Figure 13] 1 shows a schematic map of plasmid pBr / sAd4310A.RsrII-rITR.dE3.dE4 relative to its parent plasmid pBr / sAd4310A.RsrII-rITR.dE3. [Figure 14] 1 illustrates the cloning strategy used to obtain plasmid sAdApt4310A.E1btg.Empty and a schematic map of sAdApt4310A.E1btg.Empty relative to that of its parent plasmid sAdApt4310A.Empty. [Figure 15] Schematic map of the genomic organization of sAd4312. [Figure 16] 1 is a schematic map of plasmid sAdApt4312.Empty. [Figure 17] 1 is a schematic map of plasmid pBr / sAd4312.pIX-pV. [Figure 18] 1 is a schematic map of plasmid pBr / sAd4312.pV-rITR. [Figure 19] 1 illustrates the cloning strategy used to obtain plasmid pBr / sAd4312.pV-rITR.dE3 and a schematic map of pBr / sAd4312.pV-rITR.dE3 relative to that of its parent plasmid pBr / sAd4312.pV-rITR. [Figure 20] 1 shows a schematic map of plasmid pBr / sAd4312.pV-rITR.dE3.dE4 relative to its parent plasmid pBr / sAd4312.pV-rITR.dE3. [Figure 21] 1 is a schematic map of plasmid sAdApt4312.E1btg.Empty. [Figure 22A] Pie charts depicting relative sAd4287-specific neutralizing antibody (NAb) responses in sub-Saharan humans (n=144; top) and rhesus macaques (n=108; bottom). The relative numbers of individuals falling into each of four NAb titer categories (<18=negative, 18-200=low, 201-1000=high, and >1000=high) as assessed by a luciferase-based virus neutralization assay are shown. [Figure 22B] Pie charts depicting relative sAd4310A-specific neutralizing antibody (NAb) responses in sub-Saharan humans (n=144; top) and rhesus macaques (n=108; bottom). The relative numbers of individuals falling into each of four NAb titer categories (<18=negative, 18-200=low, 201-1000=high, and >1000=high) as assessed by a luciferase-based virus neutralization assay are shown. [Figure 22C]Pie charts depicting relative sAd4312-specific neutralizing antibody (NAb) responses in sub-Saharan humans (n=144; top) and rhesus macaques (n=108; bottom). The relative numbers of individuals falling into each of four NAb titer categories (<18=negative, 18-200=low, 201-1000=high, and >1000=high) as assessed by a luciferase-based virus neutralization assay are shown. [Figure 23A] Graph showing cellular responses induced by sAd4287 vector carrying SIVmac239 Gag in C57BL / 6 mice immunized with 107, 108, and 109 viral particles (vp) of the vector, assessed by measuring CD8+ T cell responses via Db / AL11 tetramer binding assay on days 0, 7, 14, 21, and 28 after immunization. [Figure 23B] Graph showing cellular responses induced by sAd4310A vector carrying SIVmac239 Gag in C57BL / 6 mice immunized with 107, 108, and 109 viral particles (vp) of the vector, assessed by measuring CD8+ T cell responses via Db / AL11 tetramer binding assay on days 0, 7, 14, 21, and 28 after immunization. [Figure 24A] Graph showing cellular responses elicited by sAd4287, sAd4310A, and replication-competent sAd4287 (rcsAd4287) at 109 vp as measured by IFN-γ ELISPOT assay using splenocytes from C57BL / 6 mice on day 28 post-immunization. IFN-γ ELISPOT responses were measured against overlapping Gag peptides (Gag), the dominant CD8+ T cell epitope AL11, the subdominant CD8+ T epitope KV9, and the CD4+ T cell epitope DD13. [Figure 24B]Graph showing cellular responses elicited by sAd4287, sAd4310A, and rcsAd4287 at 108 vp as measured by IFN-γ ELISPOT assay using splenocytes from C57BL / 6 mice on day 28 post-immunization. IFN-γ ELISPOT responses were measured against Gag, the dominant CD8+ T cell epitope AL11, the subdominant CD8+ T epitope KV9, and the CD4+ T cell epitope DD13. [Figure 24C] Graph showing cellular responses elicited by sAd4287, sAd4310A, and rcsAd4287 at 107 vp as measured by IFN-γ ELISPOT assay using splenocytes from C57BL / 6 mice on day 28 post-immunization. IFN-γ ELISPOT responses were measured against Gag, the dominant CD8+ T cell epitope AL11, the subdominant CD8+ T epitope KV9, and the CD4+ T cell epitope DD13. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0040] Detailed Description The inventors have previously identified various novel viruses, including several novel adenoviruses from rhesus macaques, as part of metagenomics studies (Handley et al. Cell. 151(2):253-266, 2012). In the present invention, the inventors isolated, amplified, and purified three novel simian adenoviruses (sAds), sAd4287, sAd4310#13-1 (sAd4310A), and sAd4312. The three sAds were obtained from the metagenomics studies of rhesus macaques described above. These viruses are entirely novel, and their full sequences have never been previously reported. These viruses have not yet been officially "named," and therefore do not yet have official adenovirus numbers. Thus, the nomenclature used throughout represents that assigned by the internal laboratory.

[0041] The complete genome sequences of the novel sAd and the vector systems that the inventors have created for each of the viruses are detailed below. The inventors have created recombinant sAd4287, sAd4310A, and sAd4312 vectors that express various transgenes, including luciferase and SIV Gag. Furthermore, the inventors have demonstrated that these vectors (i) have an unexpectedly extremely low seroprevalence in the human population, and (ii) exhibit strong immunogenicity in mice. This combination of low baseline anti-vector immunity and strong immunogenicity suggests that these novel adenoviral vectors may be useful in creating vaccines against diseases, such as cancer and those induced by infectious agents.

[0042] Polynucleotides of the Invention In a first aspect, the invention provides polynucleotide sequences for three novel sAds (sAd4287, sAd4310A, and sAd4312). The isolated polynucleotide may comprise a nucleotide sequence that is at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of any one of the full-length genomic sequences of wild-type sAd4287 (SEQ ID NO:1), sAd4310A (SEQ ID NO:2), or sAd4312 (SEQ ID NO:3), or a complement thereof. An isolated polynucleotide of the present invention may comprise at least 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 25000, 30000, 35000 or more contiguous or noncontiguous nucleotides of SEQ ID NOs: 1-3.

[0043] In some embodiments, polynucleotides of the present invention may be used as primers that are 10-100 nucleotides in length, more particularly 10-30 nucleotides in length (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length), and may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to any one of SEQ ID NOs:52-123.

[0044] In some embodiments, a polynucleotide of the invention comprises all or a portion of a nucleotide sequence encoding fiber 1, fiber 2, and / or hexon proteins of wild-type sAd4287, sAd4310A, and / or sAd4312. In some embodiments, the nucleotide sequence encoding all or a portion of the fiber 1 protein may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding fiber 1 proteins of wild-type sAd4287, sAd4310A, or sAd4312, which correspond to SEQ ID NOs: 4, 5, and 6, respectively. The polypeptide sequences of fiber 1 proteins of wild-type sAd4287, sAd4310A, and sAd4312 correspond to SEQ ID NOs: 19, 20, and 21, respectively. In some embodiments, a nucleotide sequence encoding all or a portion of a fiber 2 protein can be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding wild-type sAd4287, sAd4310A, or sAd4312 fiber 2 protein, which correspond to SEQ ID NOs:7, 8, and 9, respectively. The polypeptide sequences of wild-type sAd4287, sAd4310A, and sAd4312 fiber 2 proteins correspond to SEQ ID NOs:22, 23, and 24, respectively. In some embodiments, a nucleotide sequence encoding all or a portion of a hexon protein may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding the hexon protein of wild-type sAd4287, sAd4310A, or sAd4312, corresponding to SEQ ID NOs: 10, 11, and 12, respectively.The polypeptide sequences of the hexon proteins of wild-type sAd4287, sAd4310A, and sAd4312 correspond to SEQ ID NOs:25, 26, and 27, respectively.

[0045] In other embodiments, a polynucleotide of the invention comprises all or a portion of a nucleotide sequence encoding a knob domain of fiber 1 of wild-type sAd4287, sAd4310A, and / or sAd4312. In some embodiments, the nucleotide sequence encoding all or a portion of the fiber 1 knob domain may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding the knob domain of wild-type sAd4287, sAd4310A, or sAd4312 fiber 1 protein, which correspond to SEQ ID NOs: 13, 14, or 15, respectively. The polypeptide sequences of the knob domain of wild-type sAd4287, sAd4310A, and sAd4312 fiber 1 protein correspond to SEQ ID NOs: 28, 29, and 30, respectively. In some embodiments, a nucleotide sequence encoding all or a portion of the fiber 2 knob domain can be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to the nucleotide sequence encoding the knob domain of wild-type sAd4287, sAd4310A, or sAd4312 fiber 2 proteins, which correspond to SEQ ID NOs: 16, 17, and 18, respectively. The polypeptide sequences of the knob domain of wild-type sAd4287, sAd4310A, and sAd4312 fiber 2 proteins correspond to SEQ ID NOs: 31, 32, and 33, respectively.

[0046] In other embodiments, a polynucleotide of the invention comprises all or a portion of one or more nucleotide sequences encoding fiber 1, fiber 2, hexon, fiber 1 knob, and / or fiber 2 knob proteins of sAd4287, sAd4310A, and / or sAd4312, as well as nucleotide sequences from one or more adenoviral vectors, including Ad11, Ad15, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49, Ad50, and / or Pan9 (also known as AdC68), as specified in the generation of chimeric adenoviral vectors, as discussed below. In other embodiments, polynucleotides of the invention comprise nucleotide sequences that may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of one or more nucleotide sequences encoding fiber 1, fiber 2, hexon, fiber 1 knob, and / or fiber 2 knob proteins of sAd4287, sAd4310A, and / or sAd4312, as well as nucleotide sequences from one or more adenoviral vectors, including Ad11, Ad15, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49, Ad50, and / or Pan9 (also known as AdC68).In other embodiments, a polynucleotide of the invention comprises all or a portion of one or more nucleotide sequences that may be at least 90% identical (e.g., at least 91%, 92%, 93%, or 94% identical), at least 95% identical (e.g., at least 96%, 97%, 98%, or 99% identical), or 100% identical to all or a portion of one or more nucleotide sequences derived from one or more adenoviral vectors, including Ad5, Ad11, Ad15, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49, Ad50, and / or Pan9 (also known as AdC68), and one or more nucleotide sequences encoding fiber 1, fiber 2, hexon, fiber 1 knob, and / or fiber 2 knob proteins of sAd4287, sAd4310A, and / or sAd4312.

[0047] Vectors of the Invention The present invention also features recombinant vectors comprising any one or more of the above polynucleotides. In some embodiments, a vector of the present invention can be used in combination with one or more other vectors of the present invention (e.g., one, two, three, or more vectors) as a vector system, which can be used to generate recombinant replication-deficient sAds (rdsAds) or replication-competent sAds (rcsAds) of the present invention. Thus, the present invention features novel adenovirus vector systems for each of the three novel sAds (sAd4287, sAd4310A, and sAd4312) described herein. Such vector systems for generating replication-deficient adenoviruses are known in the art and have been applied to generate batches free of replication-competent adenoviruses, for example, based on Ad5, Ad11, Ad35 and Ad49 (see, for example, WO 97 / 00326, WO 00 / 70071; WO 02 / 40665; US 2005 / 0232900 (all incorporated herein by reference)). However, the vectors and vector systems of the present invention applied to sAd sAd4287, sAd4310A and sAd4312 are novel.

[0048] In some embodiments, vectors of the invention may include the E1 region (e.g., nt 474 to nt 3085 of sAd4287 (SEQ ID NO: 1); nt 474 to nt 3088 of sAd4310A (SEQ ID NO: 2); and nt 487 to nt 3100 of sAd4312 (SEQ ID NO: 3)) of specific sAds (e.g., sAd4287, sAd4310A, and sAd4312) for the purpose of generating replication-competent sAds (rcsAds). Such vectors are exemplified, for example, in the .E1btg.Empty vectors of the invention (see, e.g., Figures 7, 14, and 21, which show the .E1btg.Empty vectors of the invention for each of the three novel adenoviruses).

[0049] In some embodiments, the vector of the invention may include left end sAd sequences and an expression / transgene cassette (see, e.g., FIG. 3, which shows the pBr / sAd4287.pIX-pV vector, which includes the left portion of the sAd4287 genome from approximately pIX to pV). In some embodiments, the expression cassette of the vector replaces or disrupts the E1 region of a particular adenovirus. In a preferred embodiment, the expression cassette includes a promoter (e.g., a CMV promoter, e.g., a CMVlong promoter) that drives expression of a transgene and, optionally, a polyadenylation signal (e.g., a heterologous nucleotide sequence encoding an antigenic gene product of interest, e.g., a bacterial, viral, parasitic, fungal, or therapeutic protein, or fragment thereof) (see, e.g., FIGS. 2, 9, and 16, which show the .Empty vector of the invention in each of the three novel adenoviruses). The E1 region may be deleted (partially or completely), disrupted, or inactivated by one or more mutations.

[0050] In some embodiments, a vector of the invention may comprise the left portion of the sAd sequence (see, e.g., Figure 3, which shows the pBr / sAd4287.pIX-pV vector, which comprises the left portion of the sAd4287 genome from approximately pIX to pV), which includes the penton base and 52K coding region of sAd (see, e.g., Figures 3, 10, and 17, which show the .pIX-pV vectors of the invention in each of the three novel adenoviruses).

[0051] In other embodiments, vectors of the invention may include the right portion of sAd sequences (see, e.g., FIG. 4, which shows a pBr / sAd4287.PsiI.rITR vector that includes the right portion of the sAd4287 genome from about pVII through the right ITR (rITR)) (see, e.g., FIGS. 4, 11, and 18, which show the .pV-rITR vectors of the invention for each of the three novel adenoviruses). In some embodiments, these vectors may further include a deleted, disrupted, or mutated E3 sequence that is not required for replication and packaging of adenoviral particles (e.g., nt 25973 to nt 28596 of sAd4287 (SEQ ID NO: 1); nt 25915 to nt 28496 of sAd4310A (SEQ ID NO: 2); and nt 25947 to nt 28561 of sAd4312 (SEQ ID NO: 3); the right portion of the sAd4287 genome that is not required for replication and packaging of adenoviral particles (see, e.g., FIG. 4, which shows a pBr / sAd4287.PsiI.rITR vector that includes the right portion of the sAd4287 genome from about pVII through the right ITR (rITR)) (see, e.g., FIG. 4, 11, and 18, which show the .pV-rITR vectors of the invention for each of the three novel adenoviruses). 5, 12, and 19, which show the .dE3 vector of the present invention) and / or the E4 region (e.g., nt 31852 to nt 34752 of sAd4287 (SEQ ID NO: 1); nt 31750 to nt 34048 of sAd4310A (SEQ ID NO: 2); and nt 31818 to nt 34116 of sAd4312 (SEQ ID NO: 3); see Figures 6, 13, and 20, which show the .dE3.dE4 vector of the present invention for each of the three novel adenoviruses). Deletion of the E3 region is generally preferred because it limits the genome size that can be packaged into a functional particle to about 105% of the wild-type size when large transgene sequences are incorporated into the vector. It should be understood that other modifications, such as deletion of most, if not all, of the E2A region, or the entire E4 region, may be introduced into the adenoviral genome, although not applicable herein. In some embodiments, cells transfected with the vectors of the present invention can complement these defects by providing functionality to the missing regions. E2A regions can be provided, for example, by temperature-sensitive E2A mutants or by providing E4 function. Cells that can be used to complement the adenoviral gene defects (e.g., E1, E3, and / or E4 deletions) of the vectors of the present invention include, for example, PER.55K, PER.C6®, and 293 cells.All such systems are known in the art, and such modifications of the adenoviral genome are included within the scope of the present invention, which in principal relates to the three novel sAd4287, sAd4310A, and sAd4312 genome sequences and their uses. As noted above, any one vector of the invention may be used in combination with one or more other vectors of the invention. In some embodiments, vectors encoding both the left and right sides of the sAd genome are used to generate a given sAd of the invention.

[0052] The invention also features vectors for the generation of chimeric adenoviruses that include a portion of the sAd4287, sAd4310A, or sAd4312 genome and a portion of the genome of one or more other viruses. In some embodiments, the chimeric adenovirus vectors of the invention may include replacement of all or a portion of the hexon and / or fiber protein. In some embodiments, the portion of the hexon protein that is replaced with a portion of another virus is a hexon protein hypervariable region (HVRs), e.g., HVR1 (nt 403 to nt 489), HVR2 (nt 520 to nt 537), HVR3 (nt 592 to nt 618), HVR4 (nt 706 to nt 744), HVR5 (nt 763 to 786), HVR6 (nt 856 to nt 874), and / or HVR7 (nt 1201 to nt 1296) (SEQ ID NO: 10) of sAd4287 hexon protein; HVR1 (nt 403 to nt 477), HVR2 (nt 505 to nt 516), HVR7 (nt 506 to nt 518) of sAd4310A hexon protein; or one or more of HVR1 (nt403 to nt474), HVR2 (nt505 to nt522), HVR3 (nt577 to nt597), HVR4 (nt685 to nt726), HVR5 (nt748 to 777), HVR6 (nt847 to nt864), and / or HVR7 (nt1192 to nt1284) of the sAd4312 hexon protein. In some embodiments, the portion of the fiber protein replaced with a portion of another virus is the fiber knob domain. In some embodiments, the replaced region is replaced with a region derived from an adenovirus that has a lower seroprevalence than that of Ad5, such as subgroup B (Ad11, Ad34, Ad35, and Ad50) and subgroup D (Ad15, Ad24, Ad26, Ad48, and Ad49) adenoviruses and simian adenoviruses (e.g., Pan9, also known as AdC68).In some embodiments, the adenoviral vector backbone of Ad5, Ad11, Ad15, Ad24, Ad26, Ad34, Ad48, Ad49, Ad50, or Pan9 / AdC68 comprises a substitution of all or part of one or more of the above-mentioned hexon HVRs of sAd4287, sAd4310A, and / or sAd4312.

[0053] Adenovirus of the Invention As discussed above, recombinant adenoviruses of the present invention derived at least in part from sAd4287, sAd4310A, and / or sAd4312 may be produced using the above vectors of the present invention. These adenoviruses may be rcsAds or rdsAds. rdsAds will include inactivation by deletion, disruption, or mutation of E1 region, and may further include inactivation by deletion, disruption, or mutation of E2, E3, and / or E4 region. In some embodiments, the adenoviruses of the present invention may include antigenic or therapeutic gene products, or fragments thereof, including bacterial, viral, parasitic, or fungal proteins, or fragments thereof. In a preferred embodiment, the antigenic gene products, or fragments thereof, are capable of eliciting a strong immune response when expressed in a host or host cell. In some embodiments, the bacterial protein, or fragment thereof, is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, Mycobacterium leprae, Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Francisella tularensis, Brucella, Burkholderia The antigen may be derived from Yersinia mallei, Yersinia pestis, Corynebacterium diphtheria, Neisseria meningitidis, Bordetella pertussis, Clostridium tetani, or Bacillus anthracis.In some embodiments, the viral protein, or fragment thereof, is selected from the group consisting of Retroviridae, Flaviviridae, Arenaviridae, Bunyaviridae, Filoviridae, Togaviridae, Poxviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, Rhabdoviridae, and / or other viruses. The virus may be derived from a virus of a viral family selected from the group consisting of: Abdoviridae, Paramyxoviridae, Picornaviridae, Hepadnaviridae, Papillomaviridae, Parvoviridae, Astroviridae, Polyomaviridae, Calciviridae, and Reoviridae.In some embodiments, the virus is selected from the group consisting of human immunodeficiency virus (HIV), human papillomavirus (HPV), hepatitis A virus (Hep A), hepatitis B virus (HBV), hepatitis C virus (HCV), Variola major, Variola minor, monkeypox virus, measles virus, rubella virus, mumps virus, varicella zoster virus (VZV), poliovirus, rabies virus, Japanese encephalitis virus, herpes simplex virus, and the like. virus (HSV), cytomegalovirus (CMV), rotavirus, influenza, Ebola virus, yellow fever virus, or Marburg virus. In some embodiments, the parasite protein, or fragment thereof, is derived from Toxoplasma gondii, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Trypanosoma spp., or Legionella spp.In some embodiments, the fungal protein, or fragment thereof, is selected from the group consisting of Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus, or Rhizopus aridis. In some embodiments, the therapeutic gene product may be an interferon (IFN) protein, factor VIII, factor IX, erythropoietin, alpha-1 antitrypsin, calcitonin, glucocerebrosidase, growth hormone, low density lipoprotein (LDL), the receptor IL-2 receptor and its antagonists, insulin, globins, immunoglobulins, catalytic antibodies, interleukins, insulin-like growth factors, superoxide dismutase, immune responder modifiers, parathyroid hormone and interferons, nerve growth factor, tissue plasminogen activator, and / or colony stimulating factors (see, e.g., U.S. Pat. No. 6,054,288, incorporated herein by reference).In some embodiments, the IFN protein is human IFN-α (e.g., IFN-α-1a, IFN-α-1b, IFN-α-2a, IFN-α-2b, and consensus IFN-α (conIFN-α; FIG. 1 ), human IFN-β (e.g., IFN-β-1a and IFN-β-1b), human IFN-γ), or IFN-τ, or an IFN protein having the same or a similar biological activity to an interferon (e.g., an IFN protein having at least the activity of human IFN-α, human IFN-β, human IFN-γ, IFN-τ, or conIFN-α). The IFN polypeptide has an amino acid sequence that is substantially identical (e.g., at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or even 100% identical) to the sequence of a polypeptide that is at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical (e.g., for certain IFN sequences, see, e.g., U.S. Pat. No. 4,695,623 and U.S. Patent Application Publication No. 2011 / 0000480, which are incorporated herein by reference).

[0054] Non-limiting examples of bacterial gene products, or fragments thereof, include 10.4, 85A, 85B, 86C, CFP-10, Rv3871, and ESAT-6 gene products, or fragments thereof, from Mycobacterium; O, H, and K antigens, or fragments thereof, from E. Coli; and protective antigen (PA), or fragments thereof, from Bacillus anthracis. Non-limiting examples of viral gene products, or fragments thereof, include Gag, Pol, Nef, Tat, Rev, Vif, Vpr, or Vpu, or fragments thereof, from HIV and other retroviruses (see, e.g., US Patent Publication No. 2012 / 0076812, incorporated herein by reference); 9D antigen, or fragments thereof, from HSV; Env, or fragments thereof, from viruses that contain all the envelope proteins. Non-limiting examples of parasitic gene products, or fragments thereof, include circumsporozoite (CS) protein, gamete surface proteins Pfs230 and Pfs48 / 45, and liver specific antigen 1 or 3 (LSA-1 or LSA-3), or fragments thereof, of Plasmodium falciparum. Non-limiting examples of fungal gene products, or fragments thereof, include any cell wall mannoprotein (e.g., Afmp1 of Aspergillus fumigatus) or surface-expressed glycoprotein (e.g., SOWgp of Coccidioides immitis).

[0055] Methods of Prevention or Treatment Using the Compositions of the Invention The pharmaceutical compositions of the invention may be used as vaccines to treat a subject (eg, a human) with a disease (eg, cancer or a disease induced by an infectious agent, such as AIDS). In particular, the compositions of the present invention may be used to treat Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, Mycobacterium leprae, Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Francisella tularensis, Brucella, Burkholderia mallei, Yersinia pestis, and the like. bacteria, including pestis, Corynebacterium diphtheria, Neisseria meningitidis, Bordetella pertussis, Clostridium tetani, or Bacillus anthracis;Retroviridae, Flaviviridae, Arenaviridae, Bunyaviridae, Filoviridae, Togaviridae, Poxviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, Rhabdoviridae, Paramyxoviridae a virus of a virus family selected from the group consisting of Paramyxoviridae, Picornaviridae, Hepadnaviridae, Papillomaviridae, Parvoviridae, Astroviridae, Polyomaviridae, Calciviridae, and Reoviridae; parasites including Plasmodium gondii, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Trypanosoma spp., or Legionella spp.;As well as Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus, or Rhizopus aridis. arrhizus;

[0056] Thus, in other non-limiting embodiments, the pharmaceutical compositions of the present invention can be used to treat acquired immune deficiency syndrome (AIDS), cancer, tuberculosis, leprosy, typhoid fever, pneumonia, meningitis, Staphylococcal exfoliative syndrome (SSSS), Litter's disease, tularemia (rabbit fever), brucellosis, glanders, bubonic plague, septicemic plague, pneumonic plague, diphtheria, whooping cough, tetanus, anthrax, hepatitis, smallpox, monkeypox, measles, mumps, rubella, chicken pox, polio, rabies, The present invention may also treat subjects (e.g., humans) with: influenza, rabies, Japanese encephalitis, herpes, mononucleosis, influenza, Ebola virus disease, hemorrhagic fever, yellow fever, Marburg disease, toxoplasmosis, malaria, trypanosomiasis, legionnaires' disease, aspergillosis, blastomycosis, candidiasis (thrush), coccidioidomycosis, cryptococcosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis, or zygomycosis of the orbital sinus.

[0057] Pharmaceutical Formulations and Administration of the Compositions of the Invention Administration The pharmaceutical compositions of the present invention may be administered to a subject (e.g., a human) before or after exposure to an infectious agent (e.g., a bacterium, a virus, a parasite, a fungus), or before or after diagnosis of a disease that does not have a traceable etiology to an infectious agent (e.g., cancer), to treat, prevent, ameliorate, inhibit the progression of, or reduce the severity of, one or more symptoms of the disease in the subject. For example, the compositions of the present invention may be administered to a subject to be treated who has AIDS. Examples of the symptoms of diseases induced by viral infection, such as AIDS, that can be treated using the compositions of the present invention include, for example, fever, muscle pain, cough, sneezing, runny nose, sore throat, headache, chills, diarrhea, vomiting, rash, weakness, dizziness, bleeding under the skin, bleeding inside the body, or bleeding from body openings such as mouth, eyes, or ears, shock, nervous system dysfunction, delirium, seizures, renal failure, personality changes, neck stiffness, dehydration, seizures, lethargy, paralysis of the limbs, confusion, back pain, loss of sensation, impaired bladder and bowel function, and drowsiness that can progress to coma or death.These symptoms and their resolution during treatment may be determined, for example, by a physician during a physical examination, or by other tests and methods known in the art.

[0058] The compositions utilized in the methods described herein may be formulated for administration, for example, intramuscularly, intravenously, intradermally, transdermally, intraarterially, intralesionally, intracranially, intraarticularly, intraprostatically, intrathoracically, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilical cavities, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by direct local irrigation bathing target cells, by catheter, by lavage, by tube feeding, as a cream, or as a lipid composition.

[0059] The preferred method of administration may vary depending on various factors, such as the components of the composition being administered and the severity of the condition being treated. Formulations suitable for oral or nasal administration may consist of an effective amount of the composition dissolved in a liquid solution, such as a diluent (e.g., water, saline, or PEG-400), capsules, sachets, tablets, or gels, each containing a predetermined amount of the chimeric Ad5 vector composition of the present invention. The pharmaceutical composition may also be an aerosol formulation, for example, for inhalation into the bronchial passages. The aerosol formulation may be mixed with a pressurized pharma- ceutical acceptable propellant, such as dichlorodifluoromethane, propane, or nitrogen. In particular, administration by inhalation may be performed by using an aerosol containing, for example, sorbitan trioleate or oleic acid, together with, for example, trichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethane, or any other biologically compatible propellant gas.

[0060] The immunogenicity of the compositions of the present invention can be significantly improved when co-administered with an immunostimulant or adjuvant. Suitable adjuvants known to those skilled in the art include, for example, aluminum phosphate, aluminum hydroxide, QS21, Quil A (and its derivatives and components), calcium phosphate, calcium hydroxide, zinc hydroxide, glycolipid analogs, octodecyl esters of amino acids, muramyl dipeptide, polyphosphazene, lipoproteins, ISCOM matrix, DC-Chol, DDA, cytokines, and other adjuvants and their derivatives.

[0061] The pharmaceutical compositions according to the invention described herein may be formulated to release the composition immediately after administration (e.g., targeted delivery) or at any predetermined time after administration using controlled or sustained release formulations. Administration of the pharmaceutical compositions in controlled or sustained release formulations allows the compositions, either alone or in combination, to (i) exhibit a narrow therapeutic index (e.g., a small difference between the plasma concentration that produces adverse side effects or toxic reactions and the plasma concentration that produces a therapeutic effect; generally, the therapeutic index, TI, is greater than or equal to the median effective dose (ED 50 ) to the median lethal dose (LD 50 ) ratio); (ii) a narrow absorption window at the site of release (e.g., the gastrointestinal tract); or (iii) a short biological half-life, which are useful when frequent dosing during the day is required to maintain therapeutic levels.

[0062] Many methods can be pursued to obtain controlled or sustained release, such that the rate of release of the pharmaceutical composition exceeds the rate of metabolism. For example, controlled release can be obtained by appropriate selection of formulation parameters and ingredients, including, for example, suitable controlled release compositions and coatings. Suitable formulations are known to those skilled in the art. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles, patches, and liposomes.

[0063] The compositions of the invention may be administered to provide pre-exposure prophylaxis or after a subject has been diagnosed with a disease (e.g., cancer) that does not have a traceable etiology to an infectious agent or after the subject has been exposed to an infectious agent, such as a bacterium, virus, parasite, or fungus. The compositions may be administered to a subject, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 35, 40, 45, 50, 55, or 60 minutes, 2, 4, 6, 10, 15, or 24 hours, 2, 3, 5, or 7 days, 2, 4, 6 or 8 weeks, or even 3, 4, or 6 months prior to exposure or diagnosis, or may be administered to a subject 15-30 minutes or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 20, 24, 48, or 72 hours, 2, 3, 5, or 7 days, 2, 4, 6 or 8 weeks, 3, 4, 6, or 9 months, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 years or more after diagnosis or exposure to an infectious agent.

[0064] When treating a disease (e.g., AIDS or cancer), the compositions of the invention may be administered to a subject prior to the onset or definitive diagnosis of symptoms or after the diagnosis or symptoms become evident. For example, the compositions may be administered, for example, immediately after diagnosis or clinical recognition of a symptom, or 2, 4, 6, 10, 15, or 24 hours, 2, 3, 5, or 7 days, 2, 4, 6, or 8 weeks, or even 3, 4, or 6 months after diagnosis or detection of a symptom.

[0065] The compositions may be sterilized by conventional sterilization techniques or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is or lyophilized, and the lyophilized preparations may be administered in powder form or combined with a sterile aqueous carrier prior to administration. The pH of the formulation will typically be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, e.g., 7 to 7.5. The resulting solid form of the composition may be packaged in a plurality of single-dose units, each containing a quantity of a recombinant replication-deficient sAd vector (e.g., sAd4287, sAd4310A, or sAd4312 HIV Gag delivery vector) containing a heterologous nucleic acid encoding an antigen gene product, or a fragment thereof, and one or more immunomodulatory agents, as appropriate, for example, in a sealed packaged tablet or capsule, or in a suitable dry powder inhaler (DPI) capable of administering one or more doses.

[0066] dose The dose of a composition of the invention (e.g., the number of recombinant sAd vectors encoding an antigen gene product) or the number of treatments using a composition of the invention may be increased or decreased based on the severity, frequency of occurrence, or progression of disease in a subject (e.g., based on the severity of one or more symptoms of viral infection or cancer).

[0067] The pharmaceutical compositions of the invention may be administered in a therapeutically effective amount to provide an immunogenic and / or protective effect against the target protein in diseases caused by infectious or non-infectious agents. For example, a subject may be administered at least about 1×10 3 viral particles (vp) / dose or 1 x 10 1 ~1×10 14 vp / dose, preferably 1 x 10 3 ~1×10 12 vp / dose, and more preferably 1×10 5 ~1×10 11 It may be administered in vp / dose.

[0068] The viral particles contain nucleic acid molecules encoding antigenic gene products or fragments thereof (e.g., viral structural and nonstructural proteins) and are surrounded by a protective coat (a protein-based capsid with hexon and fiber proteins, which may be derived from a single sAd of the invention or its chimeric variants). The number of viral particles may be determined, for example, based on lysis of vector particles followed by measurement of absorbance at 260 nm (see, e.g., Steel, Curr. Opin. Biotech., 1999).

[0069] The dose administered will depend on the subject to be treated (e.g., the age, weight, immune system competence, and general health of the subject being treated), the form of administration (e.g., as a solid or liquid), the mode of administration (e.g., by injection, inhalation, dry powder aerosol), and the cells to be targeted (e.g., epithelial cells, such as vascular epithelial cells, nasal mucosa epithelial cells, or pulmonary epithelial cells). The compositions are preferably administered in an amount that results in sufficient levels of the antigen or therapeutic gene product, or fragment thereof (e.g., levels of the antigen gene product that elicit an immune response without undue deleterious physiological effects in the host caused by the antigen gene product).

[0070] Furthermore, a single or multiple administrations of the compositions of the present invention may be administered to a subject (pre- or post-exposure and / or pre- or post-diagnosis) (e.g., one administration or more than one administration). For example, a subject who is particularly susceptible to, for example, viral infection may require multiple treatments to establish and / or maintain protection against the virus. The level of induced immunity provided by the pharmaceutical compositions described herein may be monitored, for example, by measuring the amount of neutralizing secreted and serum antibodies. The dose may then be adjusted or repeated administration may be used as necessary to elicit the desired level of immune response. For example, the immune response elicited by a single administration of the compositions of the present invention (priming) may not be strong and / or long-lasting enough to provide effective protection. Thus, in some embodiments, repeated administrations (boosters) to the extent that a prime boost regimen is established may significantly boost humoral and cellular responses to the antigens of the composition.

[0071] Alternatively, the effectiveness of treatment may be determined by monitoring the level of antigen or therapeutic gene product, or fragment thereof, expressed in a subject (e.g., human) after administration of the composition of the present invention. For example, the antigen or therapeutic gene product, or fragment thereof, in the blood or lymph of the subject may be tested, for example, using standard assays known in the art (see, for example, Human Interferon-Alpha Multi-Species ELISA Kit (Product No. 41105) and Human Interferon-Alpha Serum Sample Kit (Product No. 41110), available from Pestka Biomedical Laboratories (PBL), Piscataway, New Jersey).

[0072] A single dose of the compositions of the invention may provide protection pre-exposure or pre-diagnosis, and a single dose administered post-exposure or post-diagnosis may function as a treatment according to the invention.

[0073] A single dose of the composition of the present invention can also be used to achieve treatment in subjects being treated for a disease. Multiple doses (e.g., 2, 3, 4, 5, or more doses) can also be administered to these subjects as needed.

[0074] Carriers, excipients, diluents The compositions of the invention include sAd5 vectors carrying heterologous nucleic acid molecules encoding antigens or therapeutic gene products, or fragments thereof. Therapeutic formulations of the compositions of the invention are prepared by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers using standard methods known in the art (Remington's Pharmaceutical Sciences (2011)). th (Eds., ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, PA). Acceptable carriers include buffers such as saline or phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or PEG.

[0075] Optionally, but preferably, the formulation contains a pharma- ceutically acceptable salt, preferably sodium chloride, preferably at about physiological concentrations. Optionally, the formulation of the invention may contain a pharma- ceutically acceptable preservative. In some embodiments, the concentration of the preservative is in the range of 0.1-2.0% (typically v / v). Suitable preservatives include those known in the pharmaceutical art. Benzyl alcohol, phenol, m-cresol, methylparaben, and propylparaben are preferred preservatives. Optionally, the formulation of the invention may contain a pharma- ceutically acceptable surfactant at a concentration of 0.005-0.02%.

[0076] The following examples are intended to illustrate the invention. They are not intended to limit the invention in any way. EXAMPLES

[0077] The practice of the present invention may employ, unless otherwise indicated, conventional techniques of molecular biology, cell biology, and recombinant DNA that are within the skill of one of ordinary skill in the art (see, e.g., Green and Sambrook, Molecular Cloning: A Laboratory Manuel, 4 th edition, 2012; Ausubel, et al. Current Protocols in Molecular Biology, 1987; Methods in Enzymology. Academic Press, Inc.; and MacPherson et al. PCR2: A Practical Approach, 1995).

[0078] [Example 1. Sequence of simian adenovirus sAd4287] The complete genome sequence of simian adenovirus sAd4287 was determined after isolation, amplification, and purification of the novel virus obtained from Handley et al.'s rhesus metagenomics study (Cell. 151(2):253-266, 2012). The resulting sequence of the sAd4287 genome (35079 nucleotides (nt)) is shown in SEQ ID NO:1. The schematic genome structure of sAd4287 is shown in FIG. 1. Using the complete genome sequence in an NCBI web-based BLAST search, the virus most closely related to sAd4287 was identified as simian adenovirus 1 (sAd1) ATCC VR-195 (query coverage: 93%; maximum identity: 98%). An NCBI web-based BLAST search was further performed to evaluate the homology of the three major capsid proteins (fiber 1, fiber 2, and hexon proteins) of sAd4287. The protein most closely related to sAd4287 fiber 1 was identified as sAd1 fiber 1 (query range: 100%; maximum identity: 74%). The protein most closely related to sAd4287 fiber 2 was identified as sAd7 long fiber (query range: 100%; maximum identity: 97%). The protein most closely related to sAd4287 hexon was identified as sAd1 hexon (query range: 100%; maximum identity: 93%).

[0079] Example 2. Construction of recombinant sAd4287 virus Here, we describe the construction of a sAd4287 plasmid-based system for generating recombinant sAd4287 vectors in a safe and efficient manner. The plasmid system consists of a first plasmid, termed the adapter plasmid, containing sAd4287 nucleotides 1-460, including the left inverted terminal repeat (lITR) and packaging signal, an expression cassette, and an sAd4287 fragment corresponding to nucleotides 2966-5466. The expression cassette contains a human CMV promoter, multiple cloning sites (MCS), and an SV40 polyadenylation signal (polyA), as previously shown (see, e.g., WO 00 / 70071). The adapter plasmid is based on pAdApt26.Empty (Abbink, et al., J. Virol. 81(9):4654-4663, 2007), albeit here constructed to contain sAd4287-derived sequences rather than Ad26-derived sequences. Additionally, the system may comprise other plasmids which together comprise the sAd4287 sequence between nucleotides 2966 to 35079, and in which the E1 region (nt 474 to nt 3085 of SEQ ID NO:1), E3 region (nt 25973 to nt 28596 of SEQ ID NO:1), and / or E4 region (nt 31852 to nt 34752 of SEQ ID NO:1) sequences may be deleted.

[0080] Generation of adapter plasmid sAdApt4287.Empty The plasmid used was prepared to carry the sAd4287 sequence. Primers (sAd4287.1A.fwd and sAd4287.1A.rev, SEQ ID NOs: 52 and 53, respectively) were designed to capture the first 460 nucleotides of sAd4287 by PCR and to place PacI and SalI at the 5' and 3' ends of the resulting PCR product, respectively. A second set of primers (sAd4287.1B.fwd and sAd4287.1B.rev, SEQ ID NOs: 54 and 55, respectively) were designed to span 2.5 kb upstream (nt 5466) from pIX (nt 2966) and to place AflII and PacI at the 5' and 3' ends, respectively. A third PCR primer set (sAd4287.TGC.fwd and sAd4287.TGC.rev, SEQ ID NO:56 and 57, respectively) was designed to derive the transgene cassette from the adaptor (AdApter) plasmid pAdApt26.Empty (Abbink, et al., J. Virol. 81(9):4654-4663, 2007) from the start of CMV to the end of polyA, with SalI and AflII sites engineered at the 5' and 3' ends, respectively. These three PCR fragments were ligated together in a four-point ligation into the pAdApt bacterial backbone obtained from pAdApt26 by PacI digestion, resulting in sAdApt4287.Empty (SEQ ID NO:34). A schematic map of sAdApt4287.Empty is shown in FIG. 2. This adapter plasmid has the left end sAd4287 sequences (1 to 460 and 2966 to 5466) with the E1 region replaced by an expression / transgene cassette containing the CMV promoter.

[0081] Construction of pBr / sAd4287.pIX-pV To allow cloning of the sAd4287 HpaI-HindIII restriction fragment, containing the 52K protein of sAd4287, a new plasmid was generated by inserting two PCR fragments into the pBr backbone. For this, primers (SEQ ID NOs: 58 and 59) were designed to obtain a PCR fragment from the start of pIX in wild-type sAd4287 across the HpaI site (nt 2966 to nt 8311) and engineered PacI and SbfI sites at the 5' and 3' ends, respectively. A second PCR fragment was generated from HindIII (nt 12761) to the end of pV (nt 16679) and engineered SbfI and PacI sites at the 5' and 3' ends, respectively. The second PCR fragment was generated using a second primer set (SEQ ID NOs: 60 and 61). These PCR fragments were ligated (PacI-SbfI-PacI) into the pBr backbone obtained from pBr / Ad26.SfiI (see, e.g., WO 2007 / 104792) by PacI digestion, resulting in the pBr / sAd4287.pIX-pV shuttle vector. Finally, the sAd4287 HpaI-HindIII restriction fragment obtained from the sAd4287 wild-type genome was ligated into the HpaI-HindIII digested pBr / sAd4287.pIX-pV shuttle vector, resulting in the complete pBr / sAd4287.pIX-pV plasmid (SEQ ID NO: 35). A schematic map of pBr / sAd4287.pIX-pV is shown in FIG. 3.

[0082] Construction of pBr / sAd4287.PsiI-rITR pBr / sAd4287.PsiI-rITR contains the sAd4287 sequence from the PsiI site at nucleotide 14053 to the end of the right inverted terminal repeat (rITR). To allow for cloning of this sequence, a new plasmid was first generated by inserting two PCR fragments into the pBr backbone. Two PCR fragments were generated such that they could be ligated together and cloned into the pBr-based backbone using the PacI restriction site. Primers were designed to obtain a PCR fragment from before the PsiI site at nt 14053, through the NdeI site (nt 18186) to approximately 4 kb upstream at nt 18234, with PacI and SbfI sites engineered at the 5' and 3' ends, respectively. A second primer set was designed to obtain a PCR fragment from the PmeI site at nt 30022 to the end of the rITR at nt 35079 with SbfI and PacI sites at the 5' and 3' ends, respectively. The sequences of the primers used to generate these two PCR fragments are shown in SEQ ID NOs: 62-65. These PCR fragments were ligated into the pBr backbone obtained from pBr / Ad26.SfiI by PacI-SbfI digestion, resulting in the pBr / sAd4287.PsiI-rITR shuttle vector. Finally, the NotI-AsiSI fragment (nt 16639 to nt 34032) was obtained from the wild-type sAd4287 genome and ligated into the pBr / sAd4287.PsiI.rITR shuttle vector, resulting in the complete pBr / sAd4287.PsiI-rITR plasmid (SEQ ID NO: 36). A schematic map of pBr / sAd4287.PsiI-rITR is shown in FIG.

[0083] Construction of pBr / sAd4287.PsiI-rITR.dE3 pBr / sAd4287.PsiI-rITR was modified to delete a portion of the E3 region spanning approximately nt 25973 to nt 28596 of sAd4287 and not required for replication and packaging of adenoviral particles. To generate pBr / sAd4287.PsiI-rITR.dE3, two PCR fragments were generated. The first PCR fragment contained pVIII from AscI to 140 bp after the polyA of pVIII (nt 8291 to 11192). The forward primer (SEQ ID NO:66) was directed to ApaLI within 100K and the reverse primer (SEQ ID NO:67) had a SpeI site designed into it. The second PCR contained the fiber region starting 100 bp before the polyA of the E3 region and continuing to a unique XbaI restriction site within the fiber 2 region (nt 13177 to 14824). The forward primer was directed 100 bp before the polyA of E3 with a SpeI site designed in it (SEQ ID NO: 68). The reverse primer was directed to the XbaI site (SEQ ID NO: 69). These two PCR fragments were ligated into pBr / sAd4287.PsiI-rITR in a three-point ligation with AscI-SpeI-XbaI to generate pBr / sAd4287.PsiI-rITR.dE3 (SEQ ID NO: 37). Figure 5 shows a schematic map of pBr / sAd4287.PsiI-rITR.dE3 as well as an overview of the cloning strategy described above for generating E3 deletion plasmids.

[0084] Construction of pBr / sAd4287.PsiI-rITR.dE3.dE4 pBr / sAd4287.PsiI-rITR.dE3 was modified to delete a portion of the E4 region, spanning approximately nt 31852 to nt 34752 of sAd4287, specifically E4orf1 to E4orf4. The modified plasmid pBr / sAd4287.PsiI-rITR.dE3.dE4 (SEQ ID NO: 38) provided an extended cloning capacity with an increased spacing of 1409 bp. To generate pBr / sAd4287.PsiI-rITR.dE3.dE4, two PCR products were generated. The first PCR fragment starts at the XbaI site and continues to the start of E4orf6. The sequences of the forward and reverse primers used to generate this first PCR fragment are shown in SEQ ID NOs: 72 and 73, respectively. The second PCR fragment starts just before E4orf1 and continues to the NotI site. The sequences of the forward and reverse primers used to generate this second PCR fragment are shown in SEQ ID NOs: 74 and 75, respectively. These PCR fragments have 30 bp overlaps with the flanking regions and 15 bp overlaps with each other at the XbaI and NotI sites (total of 30 bp). The PCR fragments were assembled into XbaI and NotI digested pBr / sAd4287.PsiI-rITR.dE3 by Gibson Assembly (New England BioLabs) to yield pBr / sAd4287.PsiI-rITR.dE3.dE4. Figure 6 shows a schematic map of pBr / sAd4287.PsiI-rITR.dE3.dE4 relative to pBr / sAd4287.PsiI-rITR.dE3.

[0085] Preparation of sAdApt4287.E1btg.Empty To clone the E1 region of sAd4287 (approximately nt 474 to nt 3085 of SEQ ID NO: 1) into sAdApt4287.Empty with the intent of generating a replicative sAd4287 (rcsAd4287), a PCR fragment was generated from wild-type sAd4287 using a forward primer (SEQ ID NO: 70) that starts approximately 30 bp before the NgoMIV site in the lITR region and continues approximately 10 bp after the polyA of the E1 region (nt 218 to nt 3137). The reverse primer (SEQ ID NO: 71) has an approximately 30 bp overlap with the start of the CMV promoter in sAdApt4287.Empty and contains a SalI restriction site. This PCR fragment was cloned into NgoMIV and SalI digested sAdApt4287.Empty using Gibson Assembly (New England BioLabs) to yield sAdApt4287.E1btg.Empty (SEQ ID NO: 39). A schematic map of sAdApt4287.E1btg.Empty and the cloning strategy described above is shown in FIG.

[0086] [Example 3. Sequence of simian adenovirus sAd4310#13-1 (sAd4310A)] The complete genome sequence of simian adenovirus sAd4310#13-1 (sAd4310A) was determined as described above for sAd4287. The resulting sequence of the sAd4310A genome (34391 nucleotides) is shown in SEQ ID NO:2. A schematic map of the genome structure of sAd4310A is shown in FIG. 8. Using the complete genome sequence in an NCBI web-based BLAST search, the virus most closely related to sAd4310A was identified as simian adenovirus 1 (sAd1) ATCC VR-195 (query coverage: 97%; maximum identity: 98%). An NCBI web-based BLAST search was further performed to evaluate the homology of the three major capsid proteins (fiber 1, fiber 2, and hexon proteins) of sAd4310A. The most closely related protein to sAd4310A fiber 1 was identified as sAd1 fiber 1 (query range: 100%; maximum identity: 99%). The most closely related protein to sAd4310A fiber 2 was identified as sAd1 fiber 2 (query range: 100%; maximum identity: 99%). The most closely related protein to sAd4310A hexon was identified as human Ad31 hexon (query range: 100%; maximum identity: 87%).

[0087] Example 4. Construction of recombinant sAd4310A virus Here, we describe the construction of a sAd4310A plasmid-based system for generating recombinant sAd4310A vectors in a safe and efficient manner. The plasmid system consists of a first plasmid, termed the adapter plasmid, containing sAd4310A nucleotides 1-461, including the left inverted terminal repeat (lITR) and packaging signal, an expression cassette, and an sAd4310A fragment corresponding to nucleotides 2903-5410. The expression cassette contains a human CMV promoter, multiple cloning sites (MCS), and an SV40 polyadenylation signal (polyA), as previously shown (see, e.g., WO 00 / 70071). The adapter plasmid is based on pAdApt26.Empty (Abbink, et al., J. Virol. 81(9):4654-4663, 2007), albeit here constructed to contain sAd4310A-derived sequences rather than Ad26-derived sequences. Additionally, the system may comprise other plasmids which together constitute the sAd4310A sequence between nucleotides 2903 to 34391, and in which the E1 region (nt 474 to nt 3088 of SEQ ID NO:2), E3 region (nt 25915 to nt 28496 of SEQ ID NO:2), and / or E4 region (nt 31750 to nt 34048 of SEQ ID NO:2) sequences may be deleted.

[0088] Construction of adapter plasmid sAdApt4310A.Empty The plasmid used was prepared to carry the sAd4310A sequence. Primers (sAd4310A.1A.fwd and sAd4310A.1A.rev, SEQ ID NOs: 76 and 77, respectively) were designed to capture the first 461 nucleotides of sAd4310A by PCR and to engineer PacI and SalI sites at the 5' and 3' ends of the resulting PCR product, respectively. A second set of primers (sAd4310A.1B.fwd and sAd4310A.1B.rev, SEQ ID NOs: 78 and 79, respectively) were designed to capture 2.5 kb upstream (nt 5410) from pIX (nt 2903) and to engineer AflII and PacI sites at the 5' and 3' ends, respectively. A third PCR primer set (sAd4310A.TGC.fwd and sAd4310A.TGC.rev, SEQ ID NO: 80 and 81, respectively) was designed to derive the transgene cassette from the adaptor (AdApter) plasmid pAdApt26.Empty (Abbink, et al., J. Virol. 81(9):4654-4663, 2007) from the start of CMV to the end of polyA, and to engineer SalI and AflII sites at the 5' and 3' ends, respectively. These three PCR fragments were ligated together in a four-point ligation into the pAdApt bacterial backbone obtained from pAdApt26 by PacI digestion, resulting in sAdApt4310A.Empty (SEQ ID NO: 40). A schematic map of sAdApt4310A.Empty is shown in FIG. 9. This adapter plasmid has the left end sAd4310A sequences (1-461 and 2903-5410) with the E1 region replaced by an expression / transgene cassette containing the CMV promoter.

[0089] Construction of pBr / sAd4310A.pIX-pV To allow cloning of the sAd4310A SrfI-SnaBI restriction fragment, which contains the 52K protein of sAd4310A, a new plasmid was generated by inserting two PCR fragments into the pBr backbone. For this, primers (SEQ ID NOs: 82 and 83) were designed to obtain a PCR fragment from the start of pIX across the SrfI site in wild-type sAd4310A (nt 2903 to nt 7224) and engineered PacI and SbfI sites at the 5' and 3' ends, respectively. A second PCR fragment was generated from SnaBI (nt 12098) in pIIIa to pVI (nt 17365) and engineered SbfI and PacI sites at the 5' and 3' ends, respectively. The second PCR fragment was generated using a second primer set (SEQ ID NOs: 84 and 85). These PCR fragments were ligated (PacI-SbfI-PacI) into the pBr backbone obtained from pBr / Ad26.SfiI (see, e.g., WO 2007 / 104792) by PacI digestion, resulting in the pBr / sAd4310A.pIX-pV shuttle vector. Finally, the sAd4310A SrfI-SnaBI restriction fragment obtained from the sAd4310A wild-type genome was ligated into the SrfI-SnaBI digested pBr / sAd4310A.pIX-pV shuttle vector, resulting in the complete pBr / sAd4310A.pIX-pV plasmid (SEQ ID NO: 41). A schematic map of pBr / sAd4310A.pIX-pV is shown in FIG. 10.

[0090] Construction of pBr / sAd4310A.RsrII-rITR pBr / sAd4310A.RsrII-rITR contains the sAd4310A sequence from the RsrII site at nucleotide 14882 to the end of the right inverted terminal repeat (rITR) at nucleotide 34391. To allow for cloning of this sequence, a new plasmid was first created by inserting two PCR fragments into the pBr backbone. Two PCR fragments were created so that they could be ligated together and cloned into the pBr-based backbone using the PacI restriction site. Primers (sAd4310A.3A.fwd and sAd4310A.3A.rev, SEQ ID NOs: 86 and 87, respectively) were designed to obtain a PCR fragment from the RsrII site at nt 14882, past the SalI site (nt 19189) to nt 19224, approximately 4.5 kb upstream, with PacI and SbfI sites designed at the 5' and 3' ends, respectively. A second primer set (sAd4310A.3B.fwd and sAd4310A.3B.rev, SEQ ID NOs: 88 and 89, respectively) was designed to obtain a PCR fragment from before the PmeI site at nt 29829 to the end of the rITR at nt 34391 with SbfI and PacI sites engineered at the 5' and 3' ends, respectively. These PCR fragments were ligated into a TOPO vector using the commercially available Zero Blunt® TOPO® PCR Cloning Kit (Invitrogen). The two PCR fragments were digested with PacI and SbfI either as PCR fragments or from the TOPO® clones and then ligated into the pBr backbone derived from pBr / Ad26.SfiI digested with PacI. Finally, the SalI-XbaI fragment (nt 19190 to nt 30014) was obtained from the wild-type sAd4310A genome and ligated into the pBr / sAd4310A.RsrII.rITR shuttle vector, resulting in the complete pBr / sAd4310A.RsrII-rITR plasmid (SEQ ID NO: 42). A schematic map of pBr / sAd4310A.RsrII-rITR is shown in FIG.

[0091] Construction of pBr / sAd4310A.RsrII-rITR.dE3 pBr / sAd4310A.RsrII-rITR was modified to delete a portion of the E3 region spanning approximately nt 25915 to nt 28496 of sAd4310A and not required for replication and packaging of adenoviral particles. Two PCR fragments were generated to generate pBr / sAd4310A.RsrII-rITR.dE3 using Gibson Assembly. The first PCR fragment (dE3AG) spanned approximately 50 bp before the SfiI site at nt 7644 to 140 bp after the polyA of pVIII. The forward and reverse primers had the sequences shown in SEQ ID NOs: 90 and 91, respectively, where the reverse primer was designed to have an overlap of approximately 25 bp with the second PCR fragment. The second PCR fragment (dE3BG) begins at nt 14641 (approximately 100 bp before the polyA of the E3 region) and continues approximately 50 bp after the XbaI site at nt 16252. The forward and reverse primers for the second PCR had the sequences shown in SEQ ID NOs: 92 and 93, respectively, where the forward primer was designed to have an approximately 25 bp overlap with the first PCR fragment. The two PCR fragments were assembled into SfiI- and XbaI-digested pBr / sAd4310A.RsrII.rITR using Gibson Assembly. The resulting plasmid pBr / sAd4310A.RsrII.rITR.dE3 (SEQ ID NO: 43) is shown in FIG. 12 along with the parent plasmid pBr / sAd4310A.RsrII.rITR.

[0092] Construction of pBr / sAd4310A.RsrII-rITR.dE3.dE4 pBr / sAd4310A.RsrII-rITR.dE3 was modified to delete a portion of the E4 region, spanning approximately nt 31750 to nt 34048 of sAd4310A, specifically E4orf1 to E4orf4. The modified plasmid pBr / sAd4310A.RsrII-rITR.dE3.dE4 (SEQ ID NO: 44) provided an extended cloning capacity with an increased spacing of 1394 bp. To generate the pBr / sAd4310A.RsrII-rITR.dE3.dE4 plasmid, two PCR products were generated. The first PCR fragment begins at the XbaI site and continues to the start of E4orf6. The sequences of the forward and reverse primers used to generate this first PCR fragment are shown in SEQ ID NOs: 96 and 97, respectively. The second PCR fragment begins just before E4orf1 and continues to the NotI site. The sequences of the forward and reverse primers used to generate this second PCR fragment are shown in SEQ ID NOs: 98 and 99, respectively. These PCR fragments have a 30 bp overlap with the flanking regions and a 15 bp overlap with each other at the XbaI and NotI sites (total of 30 bp). The PCR fragments were assembled by Gibson Assembly (New England BioLabs) into XbaI and NotI digested pBr / sAd4310A.RsrII-rITR.dE3 to yield pBr / sAd4310A.RsrII-rITR.dE3.dE4 (SEQ ID NO: 44). FIG. 13 shows a schematic map of pBr / sAd4310A.RsrII-rITR.dE3.dE4 relative to the parent plasmid pBr / sAd4310A.RsrII-rITR.dE3.

[0093] Preparation of sAdApt4310A.E1btg.Empty To clone the E1 region of sAd4310A (nt 474 to nt 3088 of SEQ ID NO:2) into sAdApt4310A.Empty with the intent of generating a replicative sAd4310A (rcsAd4310A), a PCR fragment was generated from wild-type sAd4310A using a forward primer (SEQ ID NO:94) that starts approximately 40 bp before the BstZ17I site in the lITR region and continues approximately 10 bp after the polyA of the E1 region (nt 150 to nt 3131). The reverse primer (SEQ ID NO:95) has an approximately 30 bp overlap with the start of the CMV promoter in sAdApt4310A.Empty and contains a SalI restriction site. This PCR fragment was cloned into BstZ17I and SalI digested sAdApt4310A.Empty using Gibson Assembly (New England BioLabs) to yield sAdApt4310A.E1btg.Empty (SEQ ID NO: 45). A schematic map of sAdApt4310A.E1btg.Empty and the cloning strategy described above is shown in FIG.

[0094] [Example 5. Sequence of simian adenovirus sAd4312] The complete genome sequence of simian adenovirus sAd4312 was determined as described above for sAd4287 and sAd4310A. The resulting sequence (34475 nucleotides) of the sAd4312 genome is shown in SEQ ID NO:3. A schematic map of the genome structure of sAd4312 is shown in FIG. 15. Using the complete genome sequence in a NCBI web-based BLAST search, the virus most closely related to sAd4312 was identified as simian adenovirus 1 (sAd1) ATCC VR-195 (query coverage: 90%; maximum identity: 98%). A further NCBI web-based BLAST search was performed to assess the homology of the three major capsid proteins of sAd4312 (fiber 1, fiber 2, and hexon proteins). The protein most closely related to sAd4312 fiber 1 was identified as human Ad52 fiber 1 (query coverage: 100%; maximum identity: 99%). The most closely related protein to sAd4312 fiber 2 was identified as sAd7 long fiber (query coverage: 99%; maximum identity: 73%). The most closely related protein to sAd4312 hexon was identified as human Ad40 hexon (query coverage: 100%; maximum identity: 89%).

[0095] Example 6. Construction of recombinant sAd4312 virus Here, we describe the construction of a plasmid-based system of sAd4312 to generate recombinant sAd4312 vectors in a safe and efficient manner. The plasmid system consists of a first plasmid, termed the adapter plasmid, containing sAd4312 nucleotides 1-472, including the left inverted terminal repeat (lITR) and packaging signal, an expression cassette, and an sAd4312 fragment corresponding to nucleotides 2939-5510. The expression cassette contains a human CMV promoter, multiple cloning sites (MCS), and an SV40 polyadenylation signal (polyA), as previously shown (see, e.g., WO 00 / 70071). The adapter plasmid is based on pAdApt26.Empty (Abbink, et al., J. Virol. 81(9):4654-4663, 2007), albeit here constructed to contain sAd4312-derived sequences rather than Ad26-derived sequences. Additionally, the system may comprise other plasmids which together comprise the sAd4312 sequence between nucleotides 2939 to 344475, and in which the E1 region (nt 487 to nt 3100 of SEQ ID NO: 3), the E3 region (nt 25947 to nt 28561 of SEQ ID NO: 3), and / or the E4 region (nt 31818 to nt 34116 of SEQ ID NO: 3) sequences may be deleted.

[0096] Preparation of adapter plasmid sAdApt4312.Empty The plasmid used was prepared to carry the sAd4312 sequence. Primers (sAd4312.1A.fwd and sAd4312.1A.rev, SEQ ID NOs: 100 and 101, respectively) were designed to capture the first 472 nucleotides of sAd4312 by PCR and to place PacI and SalI at the 5' and 3' ends of the resulting PCR product, respectively. A second set of primers (sAd4312.1B.fwd and sAd4312.1B.rev, SEQ ID NOs: 102 and 103, respectively) were designed to capture approximately 2.5 kb upstream (nt 5510) from pIX (nt 2939) and to place AflII and PacI at the 5' and 3' ends, respectively. A third PCR primer set (sAd4312.TGC.fwd and sAd4312.TGC.rev, SEQ ID NO: 104 and 105, respectively) was designed to derive the transgene cassette from the adaptor (AdApter) plasmid pAdApt26.Empty (Abbink, et al., J. Virol. 81(9):4654-4663, 2007) from the start of CMV to the end of polyA, with SalI and AflII sites engineered at the 5' and 3' ends, respectively. These three PCR fragments were ligated together in a four-point ligation into the pAdApt bacterial backbone obtained from pAdApt26 by PacI digestion, resulting in sAdApt4312.Empty (SEQ ID NO: 46). A schematic map of sAdApt4312.Empty is shown in FIG. 16. This adapter plasmid has the left end sAd4312 sequences (1 to 472 and 2939 to 5510) with the E1 region replaced by an expression / transgene cassette containing the CMV promoter.

[0097] Construction of pBr / sAd4312.pIX-pV To allow cloning of the sAd4312 BsiWI-BsiWI restriction fragment, a new plasmid was generated by inserting two PCR fragments into the pBr backbone. For this, primers (SEQ ID NO: 106 and 107) were designed to obtain a PCR fragment from the start of pIX across the BsiWI site in wild-type sAd4312 (nt 2939 to nt 6791) and engineered PacI and NdeI sites at the 5' and 3' ends, respectively. A second PCR fragment was generated from pV (nt 15564) to the RsrII site at the end of pVI (nt 17698) and engineered NdeI and PacI sites at the 5' and 3' ends, respectively. The second PCR fragment was generated using a second primer set (SEQ ID NO: 108 and 109). These PCR fragments were cloned into TOPO vectors using the commercially available Zero Blunt® TOPO® PCR cloning kit (Invitrogen), resulting in the pBr / sAd4312.pIX-pV shuttle vector. Finally, the sAd4312 BsiWI-BsiWI restriction fragment obtained from the sAd4312 wild-type genome was ligated into the BsiWI-digested pBr / sAd4312.pIX-pV shuttle vector and screened for orientation, resulting in the complete pBr / sAd4312.pIX-pV plasmid (SEQ ID NO: 47). A schematic map of pBr / sAd4312.pIX-pV is shown in FIG. 17.

[0098] Construction of pBr / sAd4312.pV-rITR pBr / sAd4312.pV-rITR contains the sAd4312 sequence from the start of pV at nucleotide 15215 to the end of the right inverted terminal repeat (rITR) at nucleotide 34475. To allow for cloning of this sequence, a new plasmid was first created by inserting two PCR fragments into the pBr backbone. Two PCR fragments were created so that they could be ligated together and cloned into the pBr-based backbone using the PacI restriction site. Primers (sAd4312.3A.fwd and sAd4312.3A.rev, SEQ ID NOs: 110 and 111, respectively) were designed to obtain a PCR fragment from the start of pV at nt 15215, past the RsrII site to nt 17698, approximately 2.5 kb upstream, with PacI and SbfI sites designed at the 5' and 3' ends, respectively. A second primer set (sAd4312.3B.fwd and sAd4312.3B.rev, SEQ ID NOs: 112 and 113, respectively) was designed to obtain a PCR fragment from before the XbaI site at nt 31015 to the end of the rITR at nt 34475 with SbfI and PacI sites designed at the 5' and 3' ends, respectively. These PCR fragments were ligated into a TOPO vector using the commercially available Zero Blunt® TOPO® PCR Cloning Kit (Invitrogen). The two PCR fragments were digested from the TOPO® clone with SbfI and PacI and then ligated into the pBr backbone derived from pBr / Ad26.SfiI digested with PacI, resulting in the pBr / sAd4312.pV-rITR shuttle vector. Finally, the NotI-XbaI fragment (nt 16412 to nt 31083) was obtained from the wild-type sAd4312 genome and ligated into the pBr / sAd4312.pV-rITR shuttle vector, resulting in the complete pBr / sAd4312.pV-rITR plasmid (SEQ ID NO: 48). A schematic map of pBr / sAd4312.pV-rITR is shown in FIG.

[0099] Construction of pBr / sAd4312.pV-rITR.dE3 pBr / sAd4312.pV-rITR was modified to delete a portion of the E3 region spanning approximately nt 487 to nt 3100 of sAd4312 and not required for replication and packaging of adenoviral particles. To generate pBr / sAd4312.pV-rITR.dE3, two PCR fragments were generated. The first PCR fragment contains pVIII from AscI to 140 bp after the polyA of pVIII (nt 9859 to nt 12302). The forward primer (sAd4312.dE3A.fwd, SEQ ID NO:114) was directed to AscI within 100K, and the reverse primer (sAd4312.dE3A.rev, SEQ ID NO:115) has a SpeI site designed into it. The second PCR has the fiber region starting 100 bp before the polyA of the E3 region and continuing to the unique restriction site XbaI in the fiber 2 region (nt 14378 to nt 17020). The forward primer (sAd4312.dE3B.fwd, SEQ ID NO:116) directed 100 bp before the polyA of E3 has a SpeI site designed into it. The reverse primer (sAd4312.dE3B.fwd, SEQ ID NO:117) directs to the XbaI site. These two PCR fragments were ligated into pBr / sAd4312.pV-rITR in a three-point ligation with AscI-SpeI-XbaI. The resulting plasmid pBr / sAd4312.pV-rITR.dE3 (SEQ ID NO:49) is shown in FIG. 19 along with the parent plasmid, pBr / sAd4312.pV-rITR.

[0100] Construction of pBr / sAd4312.pV-rITR.dE3.dE4 pBr / sAd4312.pV-rITR.dE3 was modified to delete a portion of the E4 region, spanning approximately nt 25947 to nt 28561 of sAd4312, specifically E4orf1 to E4orf4. The modified plasmid pBr / sAd4312.pV-rITR.dE3.dE4 (SEQ ID NO:50) provided an extended cloning capacity with an increased spacing of 1393 bp. To generate the pBr / sAd4312.pV-rITR.dE3.dE4 plasmid, two PCR products were generated. The first PCR fragment starts at the NdeI site and continues to the start of E4orf6. The sequences of the forward and reverse primers used to generate this first PCR fragment are shown in SEQ ID NO:120 and 121, respectively. The second PCR fragment starts just before E4orf1 and continues to the NotI site. The sequences of the forward and reverse primers used to generate this second PCR fragment are shown in SEQ ID NO: 122 and 123, respectively. These PCR fragments have a 30 bp overlap with the flanking regions and a 15 bp overlap with each other (30 bp total) at the NdeI and NotI sites. The PCR fragments were assembled into pBr / sAd4312.pV-rITR.dE3 digested with XbaI and NotI to yield pBr / sAd4312.pV-rITR.dE3.dE4 (SEQ ID NO: 50). Figure 20 shows a schematic map of pBr / sAd4312.pV-rITR.dE3.dE4 relative to the parent plasmid pBr / sAd4312.pV-rITR.dE3.

[0101] Preparation of sAdApt4312.E1btg.Empty A PCR fragment was generated from wild-type sAd4312 containing the complete E1 region of sAd4312 to clone the E1 region of sAd4312 (nt 487-3100 of SEQ ID NO: 3) into sAdApt4312.Empty with the intention of generating a replicative sAd4312 (rcsAd4312). The forward primer (SEQ ID NO: 118) is directed approximately 40 bp before the first BstZ17I site in the lITR region. The reverse primer (SEQ ID NO: 119) has an approximately 30 bp overlap with the start of the CMV promoter in sAdApt4312.Empty. The generated PCR fragment was cloned into BstZ17I and SalI digested sAdApt4312.Empty using Gibson Assembly (New England BioLabs) to obtain sAdApt4312.E1btg.Empty (SEQ ID NO: 51). In this cloning step, only the AdApt plasmid was digested with the restriction enzyme, while the PCR product was not digested. A schematic map of sAdApt4312.E1btg.Empty and the above cloning strategy is shown in FIG.

[0102] Example 7. Seroprevalence of sAd4287, sAd4310A, and sAd4312 in Sub-Saharan Humans and Rhesus Macaques The inventors next evaluated the titers of sAd4287, sAd4310A, and sAd4312 in 144 sub-Saharan humans and 108 rhesus macaques (Figures 22A-22C). Adenovirus-specific neutralizing antibody (NAb) titers were measured by a luciferase-based virus neutralization assay as previously described (Sprangers et al. J. Clin. Microbiol. 41:5046-5052, 2003; Barouch et al. Vaccine. 29:5203-5209, 2011). According to this assay, a titer of <18 is considered negative, 18-200 is considered low, 201-1000 is considered high, and >1000 is considered very high. According to data known in the art, titers >200 are suspected to be more likely to be inhibitory. Representative pie charts summarizing the relative numbers of individuals (human or monkey) falling into each of the four titer categories are shown for each of the three adenoviruses tested (see Figures 22A-22C).

[0103] The results of seroprevalence studies demonstrate that the majority of sub-Saharan humans and rhesus macaques tested exhibit negative (<18) or low (18-200) NAb titers to each of the three adenoviruses tested (sAd4287, sAd4310A, and sAd4312). These seroprevalence studies demonstrate that sAd4287, sAd4310A, and sAd4312 vectors have unexpectedly extremely low seroprevalence in human (e.g., sub-Saharan human) and monkey (e.g., rhesus) populations. The extremely low seroprevalence of the sAd vectors of the present invention is in stark contrast to the relatively high seroprevalence of Ad5 in human populations. Thus, these studies indicate that the use of vaccines containing all or part of recombinant sAd4287, sAd4310A, and sAd4312 has clear advantages in that their neutralizing activity in most cases is unlikely to interfere with vaccine efficacy in both humans and monkeys alike.

[0104] [Example 8. Measurement of cellular responses to the recombinant adenovirus of the present invention in mice] Next, the inventors tested whether recombinant replication-defective adenoviruses based on the simian adenoviruses of the present invention (e.g., sAd4287 or sAd4310A) could induce significant immune responses in vivo.To this end, vectors were made that all contained SIVmac239 Gag inserts derived from simian immunodeficiency virus (SIV).Recombinant DNA, such as the required adapter plasmids, and recombinant viruses were made as generally described (Lemckert et al.J.Virol.79:9694-9701,2005).

[0105] C57BL / 6 mice were injected with various amounts of viral vector: 7 , 10 8 , and 10 9 10 ... b CD8 / AL11 tetramer binding assay + This was performed and measured by assessing T cell-mediated responses (Barouch et al. J. Immunol. 172:6290-6297, 2004). The tetrameric H-2D folds around the immunodominant SIV Gag AL11 epitope (AAVKNWMTQTL) (Liu et al., J. Virol. 80:11991-11997, 2006). b A complex was prepared and SIV Gag-specific CD8 + T lymphocyte responses were measured on days 0, 7, 14, 21, and 28 after immunization. For the immunogenicity experiments with sAd4287 and sAd4310A, the results are shown in Figures 23A and 23B. These results indicate that the adenoviral vectors of the present invention are effective in mice, particularly at 10 8 or 10 9 It can be concluded that the vp dose shows strong immunogenicity.

[0106] To assess functional responses, splenocytes obtained on day 28 were used in an IFN-γ ELISPOT assay. 7 , 108 , and 10 9 Overlapping Gag peptides (Gag) in vps (sAd4287, sAd4310A, and rcsAd4287), dominant CD8 + T cell epitope AL11 (AAVKNWMTQTL), semi-dominant CD8 + T epitope KV9 (KSLYNTVCV), and CD4 + IFN-γ ELISPOT responses were measured against the T cell epitope DD13 (DRFYKSLRAEQTD) (Liu et al., J. Virol. 80:11991-11997, 2006). As shown in Figures 24A-24C, IFN-γ ELISPOT responses increased with increasing amounts of vp, and both Gag and AL11 responses were greater than those against the KV9 or DD13 epitopes. Furthermore, these functional responses were only elicited when using the replication-deficient adenoviruses of the invention (e.g., sAd4287 and sAd4310A), but not when using the replication-competent adenoviruses of the invention (e.g., rcsAd4287). In summary, the tests of cellular responses against the recombinant adenovirus vectors of the invention clearly show strong immunogenicity in mice.

[0107] The combination of low baseline anti-vector immunity (low seroprevalence), strong immunogenicity, and novel biology suggests that the novel adenoviral vectors of the present invention may be useful in gene therapy and / or diagnostics, as well as novel vaccine candidates against human or animal pathogens, including but not limited to, HIV, SIV, cancer, malaria, and tuberculosis.

[0108] Other embodiments While the invention has been described in connection with particular embodiments thereof, it will be understood that further modifications are possible, and that this application is intended to cover any variations, uses, or adaptations of the invention which generally follow the principles of the invention and include departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and are applicable to the essential features described above.

[0109] All publications and patent applications mentioned in this application are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0110] TIFF2024160183000001.tif199141TIFF2024160183000002.tif199141TIFF2024160183000003.tif199141TIFF2024160183000004.tif199141TIFF2024160183000005.tif199141TIFF2024160183000006.tif199141TIFF2024160183000007.tif199141TIFF2024160183000008.tif199141TIFF2024160183000009.tif199141TIFF2024160183000010.tif199141TIFF2024160183000011.tif199141TIFF2024160183000012.tif199141TIFF2024160183000013.tif199141TIFF2024160183000014.tif199141TIFF2024160183000015.tif199141TIFF2024160183000016.tif199141TIFF2024160183000017.tif199141TIFF2024160183000018.tif199141TIFF2024160183000019.tif199141TIFF2024160183000020.tif199141TIFF2024160183000021.tif199141TIFF2024160183000022.tif199141TIFF2024160183000023.tif199141TIFF2024160183000024.tif199141TIFF2024160183000025.tif199141TIFF2024160183000026.tif199141TIFF2024160183000027.tif199141TIFF2024160183000028.tif199141TIFF2024160183000029.tif199141TIFF2024160183000030.tif199141TIFF2024160183000031.tif199141TIFF2024160183000032.tif199141TIFF2024160183000033.tif199141TIFF2024160183000034.tif199141TIFF2024160183000035.tif199141TIFF2024160183000036.tif199141TIFF2024160183000037.tif199141TIFF2024160183000038.tif199141TIFF2024160183000039.tif199141TIFF2024160183000040.tif199141TIFF2024160183000041.tif199141TIFF2024160183000042.tif199141TIFF2024160183000043.tif199141TIFF2024160183000044.tif199141TIFF2024160183000045.tif199141TIFF2024160183000046.tif199141TIFF2024160183000047.tif199141TIFF2024160183000048.tif199141TIFF2024160183000049.tif199141TIFF2024160183000050.tif199141TIFF2024160183000051.tif199141TIFF2024160183000052.tif199141TIFF2024160183000053.tif199141TIFF2024160183000054.tif199141TIFF2024160183000055.tif199141TIFF2024160183000056.tif199141TIFF2024160183000057.tif199141TIFF2024160183000058.tif199141TIFF2024160183000059.tif199141TIFF2024160183000060.tif199141TIFF2024160183000061.tif199141TIFF2024160183000062.tif199141TIFF2024160183000063.tif199141TIFF2024160183000064.tif199141TIFF2024160183000065.tif199141TIFF2024160183000066.tif199141TIFF2024160183000067.tif199141TIFF2024160183000068.tif199141TIFF2024160183000069.tif199141TIFF2024160183000070.tif199141TIFF2024160183000071.tif199141TIFF2024160183000072.tif199141TIFF2024160183000073.tif199141TIFF2024160183000074.tif199141TIFF2024160183000075.tif199141TIFF2024160183000076.tif199141TIFF2024160183000077.tif199141TIFF2024160183000078.tif199141TIFF2024160183000079.tif199141TIFF2024160183000080.tif199141TIFF2024160183000081.tif199141TIFF2024160183000082.tif199141TIFF2024160183000083.tif199141TIFF2024160183000084.tif199141TIFF2024160183000085.tif199141TIFF2024160183000086.tif199141TIFF2024160183000087.tif199141TIFF2024160183000088.tif199141TIFF2024160183000089.tif199141TIFF2024160183000090.tif199141TIFF2024160183000091.tif199141TIFF2024160183000092.tif199141TIFF2024160183000093.tif199141TIFF2024160183000094.tif199141TIFF2024160183000095.tif199141TIFF2024160183000096.tif199141TIFF2024160183000097.tif199141TIFF2024160183000098.tif199141TIFF2024160183000099.tif199141TIFF2024160183000100.tif199141TIFF2024160183000101.tif199141TIFF2024160183000102.tif199141TIFF2024160183000103.tif199141TIFF2024160183000104.tif199141TIFF2024160183000105.tif199141TIFF2024160183000106.tif199141TIFF2024160183000107.tif199141TIFF2024160183000108.tif199141TIFF2024160183000109.tif199141TIFF2024160183000110.tif199141TIFF2024160183000111.tif199141TIFF2024160183000112.tif199141TIFF2024160183000113.tif199141TIFF2024160183000114.tif199141TIFF2024160183000115.tif199141TIFF2024160183000116.tif199141TIFF2024160183000117.tif199141TIFF2024160183000118.tif199141TIFF2024160183000119.tif199141TIFF2024160183000120.tif199141TIFF2024160183000121.tif199141TIFF2024160183000122.tif199141TIFF2024160183000123.tif199141TIFF2024160183000124.tif199141TIFF2024160183000125.tif199141TIFF2024160183000126.tif199141TIFF2024160183000127.tif199141TIFF2024160183000128.tif199141TIFF2024160183000129.tif199141TIFF2024160183000130.tif199141TIFF2024160183000131.tif199141TIFF2024160183000132.tif199141TIFF2024160183000133.tif199141TIFF2024160183000134.tif199141TIFF2024160183000135.tif199141TIFF2024160183000136.tif199141TIFF2024160183000137.tif199141TIFF2024160183000138.tif199141TIFF2024160183000139.tif199141TIFF2024160183000140.tif199141TIFF2024160183000141.tif199141TIFF2024160183000142.tif199141TIFF2024160183000143.tif199141TIFF2024160183000144.tif199141TIFF2024160183000145.tif199141TIFF2024160183000146.tif199141TIFF2024160183000147.tif199141TIFF2024160183000148.tif199141TIFF2024160183000149.tif199141TIFF2024160183000150.tif199141TIFF2024160183000151.tif199141TIFF2024160183000152.tif199141TIFF2024160183000153.tif199141TIFF2024160183000154.tif199141TIFF2024160183000155.tif199141TIFF2024160183000156.tif199141TIFF2024160183000157.tif199141TIFF2024160183000158.tif199141TIFF2024160183000159.tif199141TIFF2024160183000160.tif199141TIFF2024160183000161.tif199141TIFF2024160183000162.tif199141TIFF2024160183000163.tif199141TIFF2024160183000164.tif199141TIFF2024160183000165.tif199141TIFF2024160183000166.tif199141TIFF2024160183000167.tif199141TIFF2024160183000168.tif199141TIFF2024160183000169.tif199141TIFF2024160183000170.tif199141TIFF2024160183000171.tif199141TIFF2024160183000172.tif199141TIFF2024160183000173.tif199141TIFF2024160183000174.tif199141TIFF2024160183000175.tif199141TIFF2024160183000176.tif199141TIFF2024160183000177.tif199141TIFF2024160183000178.tif199141TIFF2024160183000179.tif199141TIFF2024160183000180.tif199141TIFF2024160183000181.tif199141TIFF2024160183000182.tif199141TIFF2024160183000183.tif199141TIFF2024160183000184.tif199141TIFF2024160183000185.tif199141TIFF2024160183000186.tif199141TIFF2024160183000187.tif199141TIFF2024160183000188.tif199141TIFF2024160183000189.tif199141TIFF2024160183000190.tif199141TIFF2024160183000191.tif199141TIFF2024160183000192.tif199141TIFF2024160183000193.tif199141TIFF2024160183000194.tif199141TIFF2024160183000195.tif199141TIFF2024160183000196.tif199141TIFF2024160183000197.tif199141TIFF2024160183000198.tif199141TIFF2024160183000199.tif199141TIFF2024160183000200.tif199141TIFF2024160183000201.tif199141TIFF2024160183000202.tif199141TIFF2024160183000203.tif199141TIFF2024160183000204.tif199141TIFF2024160183000205.tif199141TIFF2024160183000206.tif199141TIFF2024160183000207.tif199141TIFF2024160183000208.tif199141TIFF2024160183000209.tif199141TIFF2024160183000210.tif199141TIFF2024160183000211.tif199141TIFF2024160183000212.tif199141TIFF2024160183000213.tif199141TIFF2024160183000214.tif199141TIFF2024160183000215.tif199141TIFF2024160183000216.tif199141TIFF2024160183000217.tif199141TIFF2024160183000218.tif199141TIFF2024160183000219.tif199141TIFF2024160183000220.tif199141TIFF2024160183000221.tif199141TIFF2024160183000222.tif199141TIFF2024160183000223.tif199141TIFF2024160183000224.tif199141TIFF2024160183000225.tif199141TIFF2024160183000226.tif199141TIFF2024160183000227.tif199141TIFF2024160183000228.tif199141TIFF2024160183000229.tif199141TIFF2024160183000230.tif199141TIFF2024160183000231.tif199141TIFF2024160183000232.tif199141TIFF2024160183000233.tif199141TIFF2024160183000234.tif199141TIFF2024160183000235.tif199141TIFF2024160183000236.tif199141TIFF2024160183000237.tif199141TIFF2024160183000238.tif199141TIFF2024160183000239.tif199141TIFF2024160183000240.tif199141TIFF2024160183000241.tif199141TIFF2024160183000242.tif199141TIFF2024160183000243.tif199141TIFF2024160183000244.tif199141TIFF2024160183000245.tif199141TIFF2024160183000246.tif199141TIFF2024160183000247.tif199141TIFF2024160183000248.tif199141TIFF2024160183000249.tif199141TIFF2024160183000250.tif199141TIFF2024160183000251.tif199141TIFF2024160183000252.tif199141TIFF2024160183000253.tif199141TIFF2024160183000254.tif199141TIFF2024160183000255.tif199141TIFF2024160183000256.tif199141TIFF2024160183000257.tif199141TIFF2024160183000258.tif199141TIFF2024160183000259.tif199141TIFF2024160183000260.tif199141TIFF2024160183000261.tif199141TIFF2024160183000262.tif199141TIFF2024160183000263.tif199141TIFF2024160183000264.tif199141TIFF2024160183000265.tif199141TIFF2024160183000266.tif199141TIFF2024160183000267.tif199141TIFF2024160183000268.tif199141TIFF2024160183000269.tif199141TIFF2024160183000270.tif199141TIFF2024160183000271.tif199141TIFF2024160183000272.tif199141TIFF2024160183000273.tif199141TIFF2024160183000274.tif199141TIFF2024160183000275.tif199141TIFF2024160183000276.tif199141TIFF2024160183000277.tif199141TIFF2024160183000278.tif199141TIFF2024160183000279.tif199141TIFF2024160183000280.tif199141TIFF2024160183000281.tif199141TIFF2024160183000282.tif199141TIFF2024160183000283.tif199141.

Claims

1. An isolated polynucleotide comprising a nucleotide sequence that is at least 90% identical to or complementary to all or a portion of any one of SEQ ID NOs:1-3.

2. 2. The isolated polynucleotide of claim 1, wherein the nucleotide sequence is at least 95% identical to or complementary to all or a portion of any one of SEQ ID NOs: 1-3.

3. 3. The isolated polynucleotide of claim 2, wherein the nucleotide sequence is 100% identical to or complementary to all or a portion of any one of SEQ ID NOs: 1-3.

4. 4. The isolated polynucleotide of claim 3, wherein the nucleotide sequence comprises all or a portion of any one of SEQ ID NOs: 4-12, or a complementary sequence thereof.

5. 5. The isolated polynucleotide of claim 4, wherein the nucleotide sequence comprises all or a portion of any one of SEQ ID NOs:13-18.

6. A recombinant vector comprising the isolated polynucleotide of any one of claims 1 to 5.

7. The recombinant vector of claim 6, wherein the vector is an sAd4297 adenoviral vector comprising any one of SEQ ID NOs: 34-39.

8. The recombinant vector of claim 6, wherein the vector is an sAd4310A adenoviral vector comprising any one of SEQ ID NOs: 40-45.

9. The recombinant vector of claim 6, wherein the vector is an sAd4312 adenoviral vector comprising any one of SEQ ID NOs: 46-51.

10. A recombinant adenovirus comprising the isolated polynucleotide of any one of claims 1 to 5.

11. The recombinant adenovirus of claim 10, wherein the isolated polynucleotide comprises a deletion in or of the E1 region, which deletion renders the recombinant virus replication-deficient.

12. 12. The recombinant adenovirus of claim 11, wherein the isolated polynucleotide comprises a deletion within the E3 and / or E4 region or a deletion within the E3 and / or E4 region.

13. 13. The recombinant adenovirus of claim 11 or 12, further comprising a heterologous nucleotide sequence encoding an antigenic or therapeutic gene product of interest, or a fragment thereof.

14. 14. The recombinant adenovirus of claim 13, wherein the antigenic gene product, or fragment thereof, comprises a bacterial, viral, parasitic, or fungal protein, or fragment thereof.

15. The bacterial protein, or a fragment thereof, is selected from Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, Mycobacterium leprae, Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Klebsiella pneumoniae, and the like. pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Francisella tularensis, Brucella, Burkholderia mallei, Yersinia pestis, Corynebacterium diphtheria, Neisseria meningitidis, Bordetella pertussis, Clostridium tetanus 15. The recombinant adenovirus of claim 14, which is derived from Bacillus tetani, or Bacillus anthracis.

16. The viral protein, or a fragment thereof, may be a member of the family Retroviridae, Flaviviridae, Arenaviridae, Bunyaviridae, Filoviridae, Togaviridae, Poxviridae, Herpesviridae, Orthomyxoviridae, Coronaviridae, Rhabdoviridae, or a family of viruses.

15. The recombinant adenovirus of claim 14, which is derived from a viral family selected from the group consisting of: Paramyxoviridae, Picornaviridae, Hepadnaviridae, Papillomaviridae, Parvoviridae, Astroviridae, Polyomaviridae, Calciviridae, and Reoviridae.

17. The viral protein, or a fragment thereof, may be selected from the group consisting of human immunodeficiency virus (HIV), human papillomavirus (HPV), hepatitis A virus (Hep A), hepatitis B virus (HBV), hepatitis C virus (HCV), variola major, variola minor, monkeypox virus, measles virus, rubella virus, and the like. virus, mumps virus, varicella zoster virus (VZV), poliovirus, rabies virus, Japanese encephalitis virus, herpes simplex virus (HSV), cytomegalovirus (CMV), rotavirus, influenza, Ebola virus, yellow fever virus, or Marburg virus.

17. The recombinant adenovirus of claim 16, derived from a recombinant adenovirus of the present invention.

18. 18. The recombinant adenovirus of claim 17, wherein the viral protein, or fragment thereof, is derived from HIV Gag, Pol, Env, Nef, Tat, Rev, Vif, Vpr, or Vpu.

19. 15. The recombinant adenovirus of claim 14, wherein the parasite protein, or fragment thereof, is derived from Toxoplasma gondii, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Trypanosoma spp., or Legionella spp.

20. The fungal protein, or a fragment thereof, is selected from the group consisting of Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, Paracoccidioides brasiliensis, Sporothrix schenckii, and the like. schenckii, Zygomycetes spp., Absidia corymbifera, Rhizomucor pusillus, or Rhizopus arrhizus.

21. A method for treating a subject having a disease, comprising administering to the subject a recombinant adenovirus according to any one of claims 10 to 20.

22. 22. The method of claim 21, wherein the recombinant adenovirus comprises an antigenic gene product, or a fragment thereof, that promotes an immune response in the subject against an infectious agent.

23. 22. The method of claim 21, wherein the infectious agent is a bacterium, a virus, a parasite, or a fungus.

24. 24. The method of claim 23, wherein the bacterium is Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium microti, Mycobacterium leprae, Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Francisella tularensis, Brucella, Bordetella mallei, Yersinia pestis, Corynebacterium diphtheriae, Neisseria meningitidis, Bordetella pertussis, Clostridium tetani, or Bacillus anthracis.

25. The virus may be a retrovirus, a flavivirus, an arenavirus, a bunyavirus, a filovirus, a togavirus, a poxvirus, a herpesvirus, an orthomyxovirus, a coronavirus, a rhabdovirus, or a rhabdovirus.

24. The method of claim 23, wherein the virus is a virus selected from the group consisting of a mycovirus, ...

26. 26. The method of claim 25, wherein the retrovirus is a human immunodeficiency virus (HIV).

27. 24. The method of claim 23, wherein the virus is human papillomavirus (HPV), hepatitis A virus (Hep A), hepatitis B virus (HBV), hepatitis C virus (HCV), variola major, variola minor, monkeypox virus, measles virus, rubella virus, mumps virus, varicella zoster virus (VZV), poliovirus, rabies virus, Japanese encephalitis virus, herpes simplex virus (HSV), cytomegalovirus (CMV), rotavirus, influenza, Ebola virus, yellow fever virus, or Marburg virus.

28. 24. The method of claim 23, wherein the parasite is Toxoplasma gondii, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Trypanosoma species, or Legionella species.

29. 24. The method of claim 23, wherein the fungus is Aspergillus, Blastomyces dermatitidis, Candida, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum var. capsulatum, South American blastocyst, Sporothrix schenckii, Zygomycete species, Absisia corymbifera, Rhizomucor pusillus, or Rhizopus arizus.

30. The disease is acquired immune deficiency syndrome (AIDS), cancer, tuberculosis, leprosy, typhoid fever, pneumonia, meningitis, staphylococcal exfoliative syndrome (SSSS), Litter's disease, tularemia (rabbit fever), brucellosis, glanders, bubonic plague, septicemic plague, pneumonic plague, diphtheria, whooping cough, tetanus, anthrax, hepatitis, smallpox, monkeypox, measles, mumps, rubella, chicken pox, polio, rabies, Japanese encephalitis, herpes, 22. The method of claim 21, wherein the disease is mononucleosis, influenza, Ebola virus disease, hemorrhagic fever, yellow fever, Marburg disease, toxoplasmosis, malaria, trypanosomiasis, legionnaires' disease, aspergillosis, blastomycosis, candidiasis (thrush), coccidioidomycosis, cryptococcosis, histoplasmosis, paracoccidioidomycosis, sporotrichosis, or orbital sinus zygomycosis.

31. The method of any one of claims 21 to 30, wherein the subject is a human.

32. 32. The method of any one of claims 21 to 31, wherein the adenovirus is administered intramuscularly, intravenously, intradermally, transcutaneously, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrathoracically, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by direct local irrigation bathing target cells, by catheter, by lavage, by tube feeding, as a cream, or as a lipid composition.

33. The method of any one of claims 21 to 32, wherein the adenovirus is administered as a pharmaceutical composition comprising a pharma- ceutically acceptable carrier.

34. 34. The method of claim 33, wherein the subject is administered at least one dose of the pharmaceutical composition.

35. 35. The method of claim 34, wherein the subject is administered at least two doses of the pharmaceutical composition.

36. 36. The method of claim 35, wherein the pharmaceutical composition is administered to the subject as a prime boost.

37. A method for producing a recombinant adenovirus according to any one of claims 10 to 20, comprising the steps of culturing cells in an appropriate medium; transfecting said cells with an isolated polynucleotide according to any one of claims 1 to 5 or a recombinant vector according to any one of claims 6 to 9; allowing replication of said polynucleotide or vector in said cells; and recovering the produced recombinant adenovirus from said medium and / or said cells.

38. 38. The method of claim 37, wherein the cell is a bacterial, plant, or mammalian cell.

39. 39. The method of claim 38, wherein the mammalian cell is a PER.55K cell or a Chinese hamster ovary (CHO) cell.

Citation Information

Patent Citations

  • Stable adenoviral vectors and methods for their propagation

    JP2005523730A